Nucleic acid sequences having gene transcription regulatory qualities

ABSTRACT

The invention is concerned with the systematic elucidation and identification of regulatory sequences. The invention provides among others screenings and detection methods with which regulatory sequences can be identified. The invention further provides regulatory sequences and use thereof in various fields such as, but not limited to, protein production, diagnostics, transgenic plants and animals, and the therapeutic field.

CROSS-REFERENCE TO RELATED APPLICATION

This application is a divisional of patent application Ser. No.10/190,312, filed Jul. 5, 2002, now U.S. Pat. No. 7,192,741, whichapplication claims priority under 35 U.S.C. § 119(e) to U.S. ProvisionalPatent Application Ser. No. 60/303,199, filed on Jul. 5, 2001, thecontents of both of which are incorporated by this reference.

STATEMENT ACCORDING TO 37 C.F.R. § 1.52(e)(5)—SEQUENCE LISTING SUBMITTEDON COMPACT DISC

Pursuant to 37 C.F.R. § 1.52(e)(1)(iii), a compact disc containing anelectronic version of the Sequence Listing has been submittedconcomitant with this application, the contents of which are herebyincorporated by reference. A second compact disc is submitted and is anidentical copy of the first compact disc. The discs are labeled “copy 1”and “copy 2,” respectively, and each disc contains one file entitled“Sequence Listing.txt” which is 531 KB and created on Jan. 9, 2003.

TECHNICAL FIELD

The invention relates to the fields of medicine and cellular biology.The invention in particular relates to means and methods for regulationof gene transcription. The invention further relates to means andmethods for determining whether a DNA sequence comprises a genetranscription modulating quality and/or a gene transcription repressingquality.

BACKGROUND

With the progression of the various genome projects, sequences of entireorganismal genomes have become available. The flood of data has raisedthe interest of many investigators. One of the more noticeablediscoveries was the observation that the human genome does not code forsignificantly more genes than the genome of simple organisms like thefruit fly. The focus of many investigators is now shifting from theidentification of genes to the determination of gene expression and genefunction. Examples of such technologies are DNA microarrays, functionalgenomics applications and proteomics. These technologies have in commonthat they are centered about the function and expression of codingsequences. However, while our knowledge of genes increases dramatically,the understanding of how the expression of the genes is regulated islimiting the ability to apply this rapidly increasing knowledge. Thisis, for instance, the case in the generation of transgenic plants andanimals and in human gene therapy. In these applications, foreignnucleic acid is typically introduced into cells to obtain expression ofcoding sequences. Often, integration of the foreign nucleic acid intothe cell's genome is required for prolonged function of the introducedsequences. However, integration of sequences into the genome can lead tounpredictability of expression because, among other things, thesurrounding DNA influences the transcription of the integratedsequences. This unpredictability is in part due to the fact thatintroduced sequences cannot be provided yet with sufficient geneticinformation to functionally isolate the integrated sequences from thetranscription influencing effects of the surrounding DNA. In anotherpart, this is due to the fact that not enough is known about thetranscription influencing effects of surrounding DNA.

SUMMARY OF THE INVENTION

Described are DNA sequences that have a capacity to influencetranscription of genes in cis. Typically, although not necessarily, theinvestigated sequences do not code by themselves for a functionalprotein. Various sequence elements with the capacity to affect genetranscription in cis, have been identified. These elements range frompromoters, enhancers, and silencers to boundary elements and matrixattachment regions.

The fact that so many different types of regulatory sequences have beendiscovered gives the impression that it is very easy to design effectiveexpression cassettes. However, quite the contrary is true. Designingexpression cassettes is still often driven by trial and error. It isquite often possible to obtain some kind of expression of a foreign genein a target cell or its progeny. However, very often it is difficult topredict with any kind of accuracy the level of expression or thepersistence of expression that an expression cassette can display in atarget cell.

Provided are, among other things, means and methods for detecting andisolating new transcription regulatory elements. A method of detecting,and optionally selecting, a DNA sequence with a genetranscription-modulating quality is provided, comprising providing atranscription system with a variety of a fragment-comprising vectors,the vectors comprising i) an element with a gene-transcriptionrepressing quality, and ii) a promoter directing transcription of areporter gene, the method further comprising performing a selection stepin the transcription system in order to identify the DNA sequence withthe gene transcription modulating quality. In certain embodiments, thefragments are located between i) the element with a gene-transcriptionrepressing quality, and ii) the promoter directing transcription of thereporter gene. RNA polymerase initiates the transcription process afterbinding to a specific sequence, called the promoter, which signals whereRNA synthesis should begin. A modulating quality can enhancetranscription from the promoter in cis, in a given cell type and/or agiven promoter. The same DNA sequence can comprise an enhancing qualityin one type of cell or with one type of promoter, whereas it cancomprise another or no gene transcription modulating quality in anothercell or with another type of promoter. Transcription can be influencedthrough a direct effect of the regulatory element (or the protein(s)binding to it) on the transcription of a particular promoter.Transcription can however, also be influenced by an indirect effect, forinstance because the regulatory element affects the function of one ormore other regulatory elements. A gene transcription modulating qualitycan also comprise a stable gene transcription quality. With stable ismeant that the observed transcription level is not significantly changedover at least 30 cell divisions. A stable quality is useful insituations wherein expression characteristics should be predictable overmany cell divisions. Typical examples are cell lines transfected withforeign genes. Other examples are transgenic animals and plants and genetherapies. Very often, introduced expression cassettes functiondifferently after increasing numbers of cell divisions or plant oranimal generations. In certain embodiments, a stable quality comprises acapacity to maintain gene transcription in subsequent generations of atransgenic plant or animal. Of course in case expression is induciblethe quality comprises the quality to maintain inducibility of expressionin subsequent generations of a transgenic plant or animal. Frequently,expression levels drop dramatically with increasing numbers of celldivisions. With a method described herein it is possible to detect andoptionally select a DNA sequence that is capable of, at least in part,preventing the dramatic drop in transcription levels with increasingnumbers of cell divisions. Thus, in one embodiment, the genetranscription modulating quality comprises a stable gene transcriptionquality. Strikingly, fragments comprising a DNA sequence with the stablegene transcription quality can be detected and optionally selected witha method of the invention, in spite of the fact that the method does notnecessarily measure long term stability of transcription. In oneembodiment, the gene transcription modulating quality comprises a stablegene transcription enhancing quality. It has been observed thatincorporation of a DNA sequence with a gene transcription modulatingquality in an expression vector with a gene of interest, results in ahigher level of transcription of the gene of interest, upon integrationof the expression vector in the genome of a cell and moreover that thehigher gene expression level is also more stable than in the absence ofthe DNA sequence with a gene transcription modulating quality.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1. The pSelect family of plasmids for selecting and characterizingSTAR elements. A resistance marker (Zeocin or puromycin) or reportergene (GFP or luciferase) under control of the promiscuous SV40 promoteris adjacent to a BamHI cloning site flanked by AscI and HindIII sites.Upstream of the cloning site are lexA operators to which lexA proteincan bind. Binding of chimeric lexA-Polycomb group proteins to theoperators causes repression of the marker or reporter gene. DNAfragments inserted at the cloning site that block repression areidentified by the persistent expression of the marker or reporter gene.The plasmid replicates episomally in cultured mammalian cells due to theoriP sequence.

FIG. 2. The pSDH family of plasmids for testing STAR elements. Twomultiple cloning sites (MCSI and MCSII) flank a reporter gene (GFP orluciferase) whose expression is driven by an upstream promoter (CMV,Tet-off, or SV40). STAR elements to be tested are inserted at MCSI andMCSII. These contain unique restriction sites (MCSI: XhoI, NotI, EcoRI,and SalI; MCSII, HindIII, EcoRV, BglII, and NheI). The plasmidreplicates after integrating at random in the genome of mammalian cells.

FIG. 3. Proportion of clones over-expressing luciferase. U-2 OS humanosteosarcoma cells were stably transfected with pSDH plasmids(containing the luciferase reporter gene under control of the tet-offpromoter), and individual transfected clones were isolated andcultivated. Luciferase expression was measured enzymatically. Theaverage luciferase expression by clones containing the STARless pSDH(“reference level”) was determined. Clones from the sets for allplasmids were scored as “over-expressing” if their luciferase activitywas more than 2-fold higher than the reference level. The percentage ofover-expressing clones in each plasmid set is plotted.

FIG. 4. Fold over-expression by over-expressing clones. The range ofover-expression in STAR-containing pSDH plasmids integrated into genomicDNA was determined by dividing the luciferase activities of each cloneby the reference level. For those displaying significant expression(more than 2-fold above the reference level), the actual fold increaseswere noted; the minimum and median values of these data are plotted foreach plasmid.

FIG. 5. Fold over-expression by over-expressing clones. The range ofover-expression in STAR-containing pSDH plasmids integrated into genomicDNA was determined by dividing the luciferase activities of each cloneby the reference level. For those displaying significant expression(more than 2-fold above the reference level), the actual fold increaseswere noted; the maximum values of these data are plotted for eachplasmid.

FIG. 6. The pSDH-CSP plasmid used for testing STAR activity. TheSecreted Alkaline Phosphatase (SEAP) reporter gene is under control ofthe CMV promoter, and the puromycin resistance selectable marker (puro)is under control of the SV40 promoter. Flanking these two genes aremultiple cloning sites into which STAR elements can be cloned. Theplasmid also has an origin of replication (ori) and ampicillinresistance gene (ampR) for propagation in Escherichia coli

FIG. 7. STAR6 and STAR49 improve predictability and yield of transgeneexpression. Expression of SEAP from the CMV promoter by CHO cellstransfected with pSDH-CSP, pSDH-CSP-STAR6, or pSDH-CSP-STAR49 wasdetermined. The STAR-containing constructs confer greater predictabilityand elevated yield relative to the pSDH-CSP construct alone.

FIG. 8. STAR6 and STAR8 improve predictability and yield of transgeneexpression. Expression of luciferase from the CMV promoter by U-2 OScells transfected with pSDH-CMV, pSDH-CMV-STAR6, or pSDH-CMV-STAR8 wasdetermined. The STAR-containing constructs confer greater predictabilityand elevated yield relative to the pSDH-CMV construct alone.

FIG. 9. Minimal essential sequences of STAR10 and STAR27. Portions ofthe STAR elements were amplified by PCR: STAR10 was amplified withprimers E23 and E12 to yield fragment 10A, E13 and E14 to yield fragment10B, and E15 and E16 to yield fragment 10C. STAR27 was amplified withprimers E17 and E18 to yield fragment 27A, E19 and E20 to yield fragment27B, and E21 and E22 to yield fragment 27C. These sub-fragments werecloned into the pSelect vector. After transfection into U-2OS/Tet-Off/LexA-HP1 cells, the growth of the cultures in the presence ofZeocin was monitored. Growth rates varied from vigorous (+++) to poor(+/−), while some cultures failed to survive Zeocin treatment (−) due toabsence of STAR activity in the DNA fragment tested.

FIG. 10. STAR element function in the context of the SV40 promoter.pSDH-SV40 and pSDH-SV40-STAR6 were transfected into the humanosteosarcoma U-2 OS cell line, and expression of luciferase was assayedwith or without protection from gene silencing by STAR6 inpuromycin-resistant clones.

FIG. 11. STAR element function in the context of the Tet-Off promoter.pSDH-Tet and pSDH-Tet-STAR6 were transfected into the human osteosarcomaU-2 OS cell line, and expression of luciferase was assayed with orwithout protection from gene silencing by STAR6 in puromycin-resistantclones.

FIG. 12. Schematic diagram of the orientation of STAR elements as theyare cloned in the pSelect vector (panel A), as they are cloned into pSDHvectors to preserve their native orientation (panel B), and as they arecloned into pSDH vector in the opposite orientation (panel C).

FIG. 13. Directionality of STAR66 function. The STAR66 element wascloned into pSDH-Tet in either the native (STAR66 native) or theopposite orientation (STAR66 opposite), and transfected into U-2 OScells. Luciferase activity was assayed in puromycin resistant clones.

FIG. 14. Copy number-dependence of STAR function. Southern blot ofluciferase expression units in pSDH-Tet-STAR10, integrated into U-2 OSgenomic DNA. Radioactive luciferase DNA probe was used to detect theamount of transgene DNA in the genome of each clone, which was thenquantified with a phosphorimager.

FIG. 15. Copy number-dependence of STAR function. The copy number ofpSDH-Tet-STAR10 expression units in each clone was determined byphosphorimagery, and compared with the activity of the luciferasereporter enzyme expressed by each clone.

FIG. 16. Enhancer-blocking and enhancer assays. The luciferaseexpression vectors used for testing STARs for enhancer-blocking andenhancer activity are shown schematically. The E-box binding site forthe E47 enhancer protein is upstream of a cloning site for STARelements. Downstream of the STAR cloning site is the luciferase geneunder control of a human alkaline phosphatase minimal promoter (mp). Thehistograms indicate the expected outcomes for the three possibleexperimental situations (see text). Panel A: Enhancer-blocking assay.Panel B: Enhancer assay.

FIG. 17. Enhancer-blocking assay. Luciferase expression from a minimalpromoter is activated by the E47/E-box enhancer in the empty vector(vector). Insertion of enhancer-blockers (scs, HS4) or STAR elements(STAR elements 1, 2, 3, 6, 10, 11, 18, and 27) block luciferaseactivation by the E47/E-box enhancer.

FIG. 18. Enhancer assay. Luciferase expression from a minimal promoteris activated by the E47/E-box enhancer in the empty vector (E47).Insertion of the scs and HS4 elements or various STAR elements (STARs 1,2, 3, 6, 10, 11, 18, and 27) do not activate transcription of thereporter gene.

FIG. 19. STAR18 sequence conservation between mouse and human. Theregion of the human genome containing 497 base pair STAR18 is shown(black boxes); the element occurs between the HOXD8 and HOXD4 homeoboxgenes on human chromosome 2. It is aligned with a region in mousechromosome 2 that shares 72% sequence identity. The region of humanchromosome 2 immediately to the left of STAR18 is also highly conservedwith mouse chromosome 2 (73% identity; gray boxes); beyond these region,the identity drops below 60%. The ability of these regions from humanand mouse, either separately or in combination, to confer growth onZeocin is indicated: −, no growth; +, moderate growth; ++, vigorousgrowth; +++, rapid growth.

FIG. 20. STAR 9 sequence (SEQ ID NO:9)

DETAILED DESCRIPTION OF THE INVENTION

In experiments designed to introduce a gene of interest into the genomeof a cell and to obtain expression of the gene of interest, thefollowing has been observed. If together with the gene of interest alsoa DNA sequence with a gene transcription modulating quality wasintroduced, more clones could be detected that expressed more than acertain amount of gene product of the gene of interest, than when theDNA sequence was not introduced together with the gene of interest. Thusthe present invention also provides a method for increasing the numberof cells expressing a more than a certain level of a gene product of agene of interest upon providing the gene of interest to the genome ofthe cells, comprising providing the cell with a DNA sequence comprisinga gene transcription modulating quality together with the gene ofinterest.

The chances of detecting a fragment with a gene transcription-modulatingquality vary with the source from which the fragments are derived.Typically, there is no prior knowledge of the presence or absence offragments with the quality. In those situations many fragments will notcomprise a DNA sequence with a gene transcription-modulating quality. Inthese situations a formal selection step for DNA sequences with thequality is introduced. This is done by selection vectors comprising thesequence on the basis of a feature of a product of the reporter gene,which can be selected for or against. For instance, the gene product mayinduce fluorescence or a color deposit (e.g., green fluorescent proteinand derivatives, luciferase, or alkaline phosphatase) or conferantibiotic resistance or induce apoptosis and cell death.

A method of the invention is particularly suited for detecting andoptionally selecting a DNA sequence comprising a genetranscription-enhancing quality. It has been observed that at least someof the selected DNA sequences, when incorporated into an expressionvector comprising a gene of interest, can dramatically increase genetranscription of the gene of interest in a host cell even when thevector does not comprise an element with a gene-transcription repressingquality. This gene transcription enhancing quality is very useful incell lines transfected with foreign genes or in transgenic animals andplants.

As used herein, the transcription system comprises host cells. Usinghost cells warrants that fragments are detected and optionally selectedwith activity in cells.

An element with a gene transcription repressing quality will, in amethod of the invention, repress transcription from a promoter in thetranscription system used. The repression does not have to lead toundetectable expression levels. Important is that the difference inexpression levels in the absence or presence of repression is detectableand optionally selectable. In certain embodiments, gene-transcriptionrepression in the vectors results in gene-transcription repressingchromatin. In these embodiments, DNA sequences can be detected, andoptionally selected that are capable of at least in part counteractingthe formation of gene-transcription repressing chromatin. In one aspect,a DNA sequence capable of at least in part counteracting the formationof gene-transcription repressing chromatin comprises a stable genetranscription quality. In certain embodiments, the DNA sequence involvedin gene-transcription repression is a DNA sequence that is recognized bya protein complex and wherein the transcription system comprises thecomplex. Preferably the complex comprises a heterochromatin-bindingprotein comprising HP1, a Polycomb-group (Pc-G) protein, a histonedeacetylase activity or MeCP2 (methyl-CpG-binding protein). Manyorganisms comprise one or more of these proteins. These proteinsfrequently exhibit activity in other species as well. The complex canthus also comprise proteins from two or more species. The mentioned setof known chromatin-associated protein complexes is able to conveylong-range repression over many base pairs. The complexes are alsoinvolved in stably transferring the repressed status of genes todaughter cells upon cell division. Sequences selected in this way areable to convey long-range anti-repression over many base pairs (van derVlag et al., 2000).

The vector used can be any vector that is suitable for cloning DNA andthat can be used in a transcription system. When host cells are used itis preferred that the vector is an episomally replicating vector. Inthis way, effects due to different sites of integration of the vectorare avoided. DNA elements flanking the vector at the site of integrationcan have effects on the level of transcription of the promoter andthereby mimic effects of fragments comprising DNA sequences with a genetranscription modulating quality. In certain embodiments, the vectorcomprises a replication origin from the Epstein-Barr virus (EBV), OriP,and a nuclear antigen (EBNA-1). Such vectors are capable of replicatingin many types of eukaryotic cells and assemble into chromatin underappropriate conditions.

In another aspect the invention provides a DNA sequence comprising i) aDNA sequence isolated from a plant or vertebrate, or derivativesthereof, or ii) a synthetic DNA sequence or one constructed by means ofgenetic engineering, which DNA sequence is a repression-inhibitingsequence which, by the method according to the present invention can bedetected, selected and optionally cloned. In another aspect, provided isa DNA sequence comprising i) a DNA sequence isolated from a plant orvertebrate, or derivatives thereof, or ii) a synthetic DNA sequence orone constructed by means of genetic engineering, which DNA sequence isdetected, selected and optionally cloned by means of the method of theinvention. Preferably the DNA sequence comprises a sequence as depictedin Table 3 or a functional homologue thereof. A functional homologue ofa sequence as depicted in Table 3 is a sequence derived with theinformation given in Table 3. For instance, a sequence that can bederived from a sequence in Table 3 by deleting, modifying and/orinserting bases in or from a sequence listed in Table 3, wherein thederived sequence comprises the same activity in kind, not necessarily inamount, of a sequence as depicted in Table 3. A functional homologue isfurther a sequence comprising a part from two or more sequences depictedin Table 3. A synthetic DNA sequence is a sequence that is not deriveddirectly or indirectly from a sequence present in an organism. Forinstance, a sequence comprising a drosophila scs or scs′ sequence is nota synthetic sequence, even when the scs or scs′ sequence wasartificially generated.

In one aspect, the invention is concerned with increasing knowledge ofhigher order gene regulation and with means and methods for utilizingthis knowledge. Whereas elements, such as classical promoters andenhancers, have been characterized that direct and regulatetranscription of single genes, higher order regulatory elements thatgovern the gene transcription capabilities of entire chromosome regionshave as yet received little attention. Much of our knowledge regardingsuch higher order elements comes from the study of embryogenesis. Duringembryogenesis, cells become committed to different developmentalpathways. Once committed, cells rarely change their fates, even aftermany cell divisions.

The stable transmission of cell type specific gene transcriptionpatterns is generally not dependent on the context of a promoter, but isinstead mediated by changes in the structure of the DNA and associatedproteins, termed chromatin. Gene regulation at the chromosomal levelinvolves modifications of DNA (e.g., methylation), histones, (e.g.,acetylation and/or methylation), and long-range interactions betweendistant chromosomal elements.

The chromatin template is a highly condensed complex of DNA, histones,and non-histone proteins, which is able to package the entire genomeinto the nucleus and simultaneously allow the appropriate transcriptionof specific genes. The eukaryotic chromosome is not a uniform templatefor the activation of gene transcription. Different types of chromatinand chromatin regions can be distinguished, which differentially affectgene transcription. The so-called heterochromatin regions identify“closed” chromatin structures whereas euchromatin is associated with amore diffuse and “open” chromatin structure. The euchromatin region canbe subject to structural changes, resulting in more or less condensedstructures, referred to as facultative heterochromatin and euchromatin.The formation of facultative euchromatin or heterochromatin is believedto represent the underlying mechanism of chromatin-mediated generegulation, keeping genes in an active or a repressed state, in a celltype specific manner.

In all eukaryotes several chromatin-associated protein complexes havebeen identified that are involved in the maintenance of cell typespecificity, one of which is the Polycomb group (PcG) complex. The PcGcomplex is involved in the stable repression of genes, in which changesin chromatin structure are believed to play an important role.Similarly, a second class of proteins, named the trithorax group (TrG),has been identified that counteracts the action of the PcG proteins. TrGproteins are involved in the maintenance of gene transcription. Based ontheir respective modes of action, PcG and TrG proteins thereforerepresent a cellular memory system that is important for the heritabletransmission of gene transcription patterns.

How PcG and TrG complexes are associated with their target genes isstill unclear. Genetic studies have characterized cis-acting regulatorysequences that maintain transcriptionally inactive states of genes. Thesilencing mediated by these cis-acting regulatory sequences is dependenton the presence of functional PcG proteins, and hence these sequenceshave been termed PcG response elements (PREs). Sequences have beenidentified that are involved in PcG mediated repression of chromatin. Asyet however, (in both vertebrates and plants) complete PREs comprisingall sequence information required to mediate repression of chromatinhave not been found.

A Polycomb-group response element is an element that is capable ofrepressing the transcription from a promoter in response to the directand/or indirect interaction of one or more Polycomb group proteins withthe element. A polycomb-group-like response element is a Polycomb-groupresponse element or alternatively it is an element capable of repressingthe transcription of a promoter upon the direct and/or indirectinteraction of one or more proteins with the element, wherein the one ormore proteins do not belong to the Polycomb-group, but wherein as aresult of the interaction gene transcription repressing chromatin isformed. Examples of such proteins are chromatin-associated proteins suchas heterochromatin protein1 (HP1) (Eisenberg et al., 1990). Anotherchromatin-associated protein that represses gene activity ismethyl-CpG-binding protein, MeCP2 (Nan et al., 1997). In certainembodiments, a polycomb-group-like responsive element of the inventioncomprises the capacity to repress transcription of a promoter over longdistances, preferably over more than 2000 base pairs (van der Vlag etal., 2000).

A reporter gene is a gene encoding an expression product of which thepresence can be detected directly or indirectly in a cell.

Examples of DNA sequences with a gene transcription modulating qualityare the so-called STAR elements listed in Tables 1 and 2.

Methods of the invention result in the cloning and identification of anumber of elements comprising a gene transcription modulating quality.Such an element may contain irrelevant nucleic acid that is notinstrumental in performing the quality, for instance not involved in theformation of gene-transcription repressing chromatin. Functionalsequences in such elements can be delineated by various methods known inthe art. In one embodiment deletions and/or substitutions are made in aDNA sequence with a gene transcription modulating quality. DNA that ismodified in such a way, is tested for activity in a method of theinvention. This can be done using a single modified nucleic acid or bygenerating a collection of test nucleic acids comprising the modifiednucleic acid. Elucidation of functional sequences within DNA sequencesof the invention enables the elucidation of consensus sequences forelements with a gene transcription modulating quality. It is anticipatedthat more than one type of consensus sequence is found for an elementcomprising a gene transcription modulating quality. The invention thusfurther provides a library of isolated and/or recombinant nucleic acidscomprising gene transcription modulating and/or gene transcriptionrepressing qualities such as polycomb-group-like response elements. Inone embodiment the library comprises isolated and/or recombinant nucleicacids comprising the same consensus sequence. In certain embodiments,the library comprises more than one type of consensus sequence. Thelibrary can be used for instance for determining whether a given DNAmolecule comprises a DNA modulating quality. In certain embodiments, thelibrary comprises essentially all elements with a gene transcriptionenhancing function, elements comprising a stable gene transcriptionquality and/or elements with a gene transcription repressing qualitysuch as polycomb-group-like response elements, of a chromosome. Togetherwith knowledge on the location of these elements on a chromosome thisallows a person skilled in the art to generate a prediction for higherorder regulation of gene expression of genes naturally present on thechromosome and for genes (foreign nucleic acid) introduced into thechromosome by recombinant means. Such a prediction can be used forexample to select a suitable candidate location on the chromosome forthe insertion of foreign DNA. A suitable location can be a locationexpected to be specifically expressed in a certain cell, cell typeand/or tissue. Preferably, the chromosome comprises chromosome 21 orchromosome 22. In a particularly preferred embodiment all DNA sequencescomprising a gene transcription modulating or a gene transcriptionrepressing quality in a cell, are in the library. In this embodiment theentire genome can be used for the prediction of a suitable candidatelocation. In one embodiment the library has been generated in differentcell lines of species ranging from plants to human. In different celllines and/or species different proteins (or protein complexes) capableof interacting with DNA sequences with a gene transcription repressingquality, will be expressed, resulting in different DNA elements with agene transcription repressing quality. Similarly different proteins thatinteract directly or indirectly with DNA sequences comprising a genetranscription modulating quality will be expressed. Therefore themake-up of the library is cell-type dependent and dependent on thepresence of the relevant proteins. This is also the case withpolycomb-group-like response elements. If HP1 is expressed in cell typeone, elements depending on HP1 will be detected by method of invention.If HP1 is not expressed in cell type two, method of invention will notdetect the element that has been retrieved from cell type one.

In one aspect, the library comprises at least one element capable of atleast in part counteracting the formation of gene-transcriptionrepressing chromatin. Together with knowledge of the location of DNAsequences with a gene transcription repressing quality on a chromosomeor genome, knowledge of the location of such counteracting elementsallows more accurate prediction of higher order regulation of genetranscription of (inserted) genes in the chromosome or genome. Thelibrary may further comprise other transcription regulatory elementssuch as enhancers and silencers. Although such sequences have limitedinfluence on higher order gene regulation, information on the locationof such other sequences further increases the accuracy of the predictionon suitable locations in the genome for the expression of foreignsequences introduced therein. The library may include essentially allDNA sequences comprising a gene transcription modulating quality and/orall other regulatory sequences of a chromosome.

Considering that already a chromosome typically consists of several tensof millions of bases, it is preferred that the information that thelibrary can give on higher order gene regulation is incorporated into anat least partially automated system.

Another use of a library is the generation of a prediction ontranscription of genes upon targeted modification of sequences on achromosome such that “higher order” regulatory sequences are mutated.For instance, one or more polycomb-group-like responsive elements of theinvention, and/or other regulatory elements on the chromosome can bemutated. This is expected to change the transcription levels of thegenes that are in the vicinity of the polycomb-group-like responsiveelements and/or other expression modulating elements.

Yet another use of a library or system is the prediction of geneexpression resulting from mutations in the genome. In cases where amutation results in altered gene transcription, detection of suchaltered gene transcription can indicate the presence of the naturallyoccurring mutation. This approach is useful for instance in limiting thenumber of sequences or proteins to be tested in a diagnostic assay. Thisis particularly important in microarray approaches because in theseapproaches the number of expressed sequences to be tested for, islimited by the number of sequences that an array can maximally hold.With means and methods of the invention it is possible to limit thenumber of sequences to be tested in microarray approaches.

Yet another use of a system or library is the discovery of drug targets.Regulatory elements, be they “higher order” elements or not, functionbecause of the protein (complexes) that can bind to them. A system ofthe invention can be used to determine whether targeting of drugs tointerfere with the binding or function of a particular protein (complex)holds promise for the alteration of expression of a particular gene.

It is also possible to provide a DNA construct with a DNA sequence ofthe invention, or to modify such a DNA sequence. In certain embodiments,a DNA construct is provided comprising a promoter operably linked with anucleic acid of interest. Preferably, the amount of activity of aquality of the DNA sequence with a gene transcription modulatingquality, is dependent on the orientation of the DNA sequence in theconstruct, compared to the promoter. The gene transcription modulatingquality may be dependent on the presence of a signal. The signal maycomprise a DNA binding protein or a human immuno-deficiency virus TATprotein.

One of the uses of a DNA sequence comprising a gene transcriptionmodulating quality is of course the regulation of transcription of agene of interest. Transcription of a gene of interest can be altered byaltering sequences in the vicinity of the gene such that a DNA sequencewith the quality is provided or removed. Specific expressioncharacteristics can be designed by combining (parts of) DNA sequenceswith a gene transcription modulating quality. For instance, duplicationof a sequence with a stable gene transcription quality in an expressionvector will lead to improved stability of expression in a target cell orprogeny upon introduction of the vector in the target cell. By combiningDNA sequences with gene transcription modulating qualities altered genetranscription modulating qualities can be generated either in kind oramount or both.

It is also possible to design DNA sequences with a desired genetranscription modulating quality. DNA binding proteins together withother proteins and DNA sequences determine qualities of the DNAsequence. It is possible to insert one or more other protein binding DNAsequences into a DNA sequence with a quality. By allowing binding of thebinding protein(s) it is possible to interfere with, or direct, thequality, thus allowing the generation of DNA sequences with designerqualities. It is also possible to remove protein binding sites from aDNA sequence with a particular gene transcription modulating qualitythereby altering the quality of the resulting DNA sequences. Thecombination of addition and removal is also possible. Particular genetranscription modulating qualities can be selected for by tuningdetection methods described in the present invention. It is, forinstance, possible to synthesize DNA sequences with inducible genetranscription modulating qualities. There are DNA binding proteinsavailable that only bind to their target sequence in the absence orpresence of a signal. Non-limiting examples of such proteins are theTET-repressor and the various mutations thereof, the lac-repressor,steroid hormone receptors, the retinoic acid receptor, and derivatives.It is possible for instance to design a DNA sequence with a cell typespecific gene transcription modulating quality. The DNA sequence can bemade specific for a protein complex that is expressed in a cell typespecific fashion.

Expression constructs comprising a DNA sequence comprising a genetranscription modulating quality are suitable for obtaining expressionfrom the construct in cells comprising more than one copy of theexpression construct. Also when the expression construct is present inthe genome of the cell and, also when the expression cassette is presentin more than one copy in the cell. Moreover, they even work whenintegrated into the same position in more than one copy.

In certain embodiments, of the invention the DNA sequence with a genetranscription modulating quality comprises a so-called STAR (StabilizingAnti-Repression) sequence. A STAR sequence as used herein refers to aDNA sequence comprising one or more of the mentioned gene transcriptionmodulating qualities.

Several methods are presented herein to determine whether a sequencecomprises STAR activity. STAR activity is confirmed if the sequence iscapable of performing at least one of the following functions: (i) atleast in part inhibiting the effect of sequence comprising a genetranscription repressing element of the invention, (ii) at least in partblocking chromatin-associated repression, (iii) at least in partblocking activity of an enhancer, (iv) conferring upon an operablylinked nucleic acid encoding a transcription unit compared to the samenucleic acid alone. (iv-a) a higher predictability of transcription,(iv-b) a higher transcription, and/or (iv-c) a higher stability oftranscription over time.

The large number of sequences comprising STAR activity identified in thepresent invention opens up a wide variety of possibilities to generateand identify sequences comprising the same activity in kind notnecessarily in amount. For instance, it is well within the reach of askilled person to alter the sequences identified in the presentinvention and test the altered sequences for STAR activity. Such alteredsequences are therefore also part of the present invention. Alterationcan include deletion, insertion and mutation of one or more bases in thesequences.

Sequences comprising STAR activity were identified in stretches of 400bases. However, it is expected that not all of these 400 bases arerequired to retain STAR activity. Methods to delimit the sequences thatconfer a certain property to a fragment of between 400 and 5000 basesare well known. The minimal sequence length of a fragment comprisingSTAR activity is estimated to be about 50 bases.

STAR activity is a feature shared by the sequences listed in SEQ ID NOs:1-65.

In another aspect, also provided is an isolated and/or recombinantnucleic acid sequence comprising a STAR sequence obtainable by a methodof the invention.

As mentioned above, a STAR sequence can exert its activity in adirectional way, i.e. more to one side of the fragment containing itthan to the other. Moreover, STAR activity can be amplified in amount bymultiplying the number of STAR elements. The latter suggests that a STARelement may comprise one or more elements comprising STAR activity.

The term quality in relation to a sequence refers to an activity of thesequence. The term STAR, STAR sequence or STAR element, as used herein,refers to a DNA sequence comprising one or more of the mentioned genetranscription modulating qualities. The term “DNA sequence” as usedherein does, unless otherwise specified, not refer to a listing ofspecific ordering of bases but rather to a physical piece of DNA. Atranscription quality with reference to a DNA sequence refers to aneffect that the DNA sequence has on transcription of a gene of interest.“Quality” as used herein refers to detectable properties or attributesof a nucleic acid or protein in a transcription system.

The invention is further described with the aid of the followingillustrative EXAMPLES.

EXAMPLES Example 1 Methods to Isolate STAR Elements

Materials and methods: Plasmids and strains. The selection vector forSTAR elements, pSelect-SV40-zeo (“pSelect”, FIG. 1) is constructed asfollows: the pREP4 vector (Invitrogen V004-50) is used as the plasmidbackbone. It provides the Epstein Barr oriP origin of replication andEBNA-1 nuclear antigen for high-copy episomal replication in primatecell lines; the hygromycin resistance gene with the thymidine kinasepromoter and polyadenylation site, for selection in mammalian cells; andthe ampicillin resistance gene and colE1 origin of replication formaintenance in Escherichia coli. The vector contains four consecutiveLexA operator sites between XbaI and NheI restriction sites (Bunker andKingston, 1994). Embedded between the LexA operators and the NheI siteis a polylinker consisting of the following restriction sites:HindIII-AscI-BamHI-AscI-HindIII. Between the NheI site and a SalI siteis the Zeocin resistance gene with the SV40 promoter and polyadenylationsite, derived from pSV40/Zeo (Invitrogen V502-20); this is theselectable marker for the STAR screen.

The pSDH vector (FIG. 2) is constructed as follows: The luciferasereporter gene from pGL3-Control (Promega E1741) is amplified by PCR andinserted into SacII/BamHI-digested pUHD10-3 (Gossen and Bujard, 1992).This places luciferase under control of the Tet-Off promoter, andupstream of the SV40 polyadenylation signal. Multiple cloning sites areintroduced by PCR, upstream of the Tet-Off promoter (MCSI,XhoI-NotI-EcoRI-SalI) and downstream of the polyadenylation signal(MCSII, NheI-BglII-EcoRV-HindIII).

Gene libraries are constructed by Sau3AI digestion of human genomic DNA,either purified from placenta (Clontech 6550-1) or carried inbacterial/P1 (BAC/PAC) artificial chromosomes. The BAC/PAC clonescontain genomic DNA from the 1q12 cytogenetic region (clones RP1154H19and RP3328E19) or from the HOX cluster of homeotic genes (clonesRP1167F23, RP1170019, and RP11387A1). The DNAs are size-fractionated,and the 0.5-2 kb size fraction is ligated into BamHI-digested pSelectvector, by standard techniques (Sambrook et al., 1989).

The construction of the host strains has been described (van der Vlag etal., 2000). Briefly, they are based on the U-2 OS human osteosarcomacell line (AMERICAN TYPE CULTURE COLLECTION® HTB-96). U-2 OS is stablytransfected with the pTet-Off plasmid (Clontech K1620-A), encoding aprotein chimera consisting of the Tet-repressor DNA binding domain andthe VP16 transactivation domain. The cell line is subsequently stablytransfected with fusion protein genes containing the LexA DNA bindingdomain, and the coding regions of either HP1 or HPC2 (two DrosophilaPolycomb group proteins that repress gene expression when tethered toDNA). The LexA-repressor genes are under control of the Tet-Offtranscriptional regulatory system (Gossen and Bujard, 1992).

Library screening and STAR element characterization. The gene librariesin pSelect are transfected into the U-2 OS/Tet-Off/LexA-repressor cellline by calcium phosphate precipitation (Graham and van der Eb, 1973;Wigler et al., 1978) as recommended by the supplier of the transfectionreagent (Life Technologies). Transfected cells are cultured underhygromycin selection (25 μg/ml) and tetracycline repression(doxycycline, 10 ng/ml) for 1 week (50% confluence). Then thedoxycycline concentration is reduced to 0.1 ng/ml to induce theLexA-repressor genes, and after 2 days Zeocin is added to 250 μg/ml. Thecells are cultured for a further 4-5 weeks, until the control cultures(transfected with empty pSelect) are killed by the Zeocin.

Zeocin-resistant colonies from the library transfection are propagated,and plasmid DNA is isolated and rescued into E. coli by standardtechniques (Sambrook et al., 1989). The candidate STAR elements in therescued DNA are analyzed by restriction endonuclease mapping (Sambrooket al., 1989), DNA sequence analysis (Sanger et al., 1977), and for STARactivity (Zeocin resistance) after re-transfection to U-2OS/Tet-Off/LexA-repressor and lowering the doxycycline concentration.

Candidate STAR elements that have DNA sequence corresponding to knownsequence in the human genome are identified by BLAST searches (Altschulet al., 1990) of the human genome database(www.ncbi.nlm.nih.gov/genome/seq/HsBlast.html 20 Jun. 2001). Thechromosomal locations of the elements are recorded, along with theproportion of repetitive DNA and the identity of adjacent genes.

Those candidates that show STAR activity upon re-transfection arecharacterized further by subcloning the STAR fragment into the pSDHplasmid and stable integration in U-2 OS chromosomal DNA. pSDH plasmidsare co-transfected into U-2 OS cells with pBABE-puro (Morgenstern andLand, 1990), and selected for puromycin resistance. Per STAR element,populations of approximately 30 individual clones are isolated andcultured. The clones are periodically assayed for luciferase activityaccording to the manufacturer's instructions (Roche 1669893).

Results: STAR element functional characterization. The screens of humangenomic DNA and of the HOX and 1q12 loci yielded 17 bona fide STARelements. The criteria are that (1) elements displayed STAR activityupon re-transfection of the pSelect-based clones into the host U-2 OShuman osteosarcoma cell line (indicating that the anti-repressoractivity expressed in the initial screen is plasmid-specific and not dueto artifactual changes in the host cells); (2) the elements contain DNAsequence that matches sequence in the human genome sequence database(indicating that the clone does not contain contaminating DNA sequence,from e.g., bacterial or vector sources).

The STAR elements are sub-cloned into the pSDH plasmid and integratedinto the host cell genome. Expression of the reporter genes is assayedin populations of stable transfectants to demonstrate the ability of theSTAR elements to protect reporter genes from silencing after integrationat random into the genome. This provides information (1) on theproportion of clones which display high expression, and (2) on thedegree of over-expression elicited by the STAR elements.

Expression of the luciferase reporter gene by a clone is consideredsignificant if it is two-fold above the average level for the plasmidscontaining no STAR elements (the reference level). For all plasmids adistribution in expression level is observed among the clones: from noexpression to expression significantly above the reference level, andfrom few over-expressers to many over-expressers. Superior STAR activityis manifested by plasmids that result in many over-expressing clones,including some highly over-expressing clones. Results from arepresentative experiment are shown in Table 1, and in FIGS. 3-5.

The results indicate that the human STAR elements which are tested yielda much higher proportion of over-expressing clones than the unprotectedreporter gene, or the reporter gene protected by the Drosophila SCSelement (Kellum and Schedl, 1992). Furthermore, the degree ofover-expression by these plasmids is much greater from theSTAR-protected reporter gene than the unprotected or SCS-protectedreporter.

STAR element sequence and genomic position data. Table 2 lists thechromosomal locations of each of the 17 STAR elements, as well as theidentity of nearby genes and the repetitive DNA content of the elements.The STAR elements are distributed over a number of chromosomes. They arediverse in their actual DNA sequence and repetitive DNA content, anddisplay various degrees of association with neighboring genes.

Example 2 Expression Characteristics of the Transgene that are Due tothe STAR

Background: site-specific recombination is used to precisely removeheterologous DNAs from their chromosomal locations. This is routinelycarried out by one of two systems: the cre recombinase and loxP targetof bacteriophage P1 (Feng et al., 1999), or the FLP recombinase and FRT(FLP recombinase target) of yeast (Wigley et al., 1994). In thesesystems, a DNA region (usually containing a reporter gene and/or aselectable marker) is flanked in the chromosome by the loxP or FRTtarget. The activity of the recombinase then catalyzes the preciseexcision of the DNA region from the chromosome. The recombinase resolvesits two recognition sequences to a single site, deleting the sequencebetween them. Thus, a span of DNA must be flanked by target sites to besubsequently deleted in vivo upon introduction or activation ofrecombinase (Schwenk et al., 1995; Dymecki, 1996). The Cre and Flprecombinases catalyze recombination between two 13-base-pair invertedrepeats, separated by a spacer with a minimum of 6 (loxP) or 8 (FRT)base pairs (Senecoff et al., 1985). The loxP sequence is ATAACTTCGTATA(SEQ ID NO: 120) and the FRT sequence is GAAGTTCCTATAC (SEQ ID NO:121).

Protocol: Using conventional DNA cloning (Sambrook et al., 1989), areporter gene (encoding a reporter protein, for example greenfluorescent protein (GFP) (Bierhuizen et al., 1997) or luciferase (Himesand Shannon, 2000) is constructed that is flanked in a plasmid by a pairof STAR elements. In each case, the elements are themselves flanked byrecombinase target sites. One element is flanked by a pair of loxPsites, and the other is flanked by a pair of FRT sites (FIG. 1). Upontransfection the plasmid integrates into the host chromosome in a smallpercentage of cells, and the integrants are selected by antibioticresistance.

Using conventional techniques, (“SUPERFECT® Transfection ReagentHandbook,” Qiagen, November, 1997) these plasmids are transfected intothe U-2 OS human osteosarcoma cell line, and selected for hygromycinresistance. Hygromycin-resistant isolates have the plasmid stablyintegrated in the genome of the cell line. Individual isolates arepropagated in cell culture medium, and the expression of the transgenicreporter gene is assayed, for example by flow cytometry (Stull et al.,2000).

Then using conventional techniques (transfection, or hormonestimulation), the stable isolates from above are treated so as tointroduce or activate recombinase activity. This is done sequentially,such that for example the cre recombinase activity catalyzes excision ofSTAR1, and subsequently FLP recombinase activity catalyzes excision ofSTAR2. The level of expression of the reporter gene in these cells isassayed and the value compared with the reference value of the parental,STAR-containing isolate.

Example 3 Sequence Analysis of STARs; Determination of Minimal EssentialSequence for Element Function; Sequence Conservation Among Elements; andProperties of Tandem and Multiple Elements

Background: DNA fragments containing STAR elements are isolated bygenetic selection using the pSelect (FIG. 1) plasmid. This sectiondescribes the approach to characterize the DNA sequences within thosefragments that have STAR activity.

Protocols: DNA sequence: Oligonucleotides are designed based on thesequence of the pSelect plasmid for sequencing the DNA fragments. Thefragments are sequenced using the dideoxy chain termination technique(Sanger et al., 1977). DNA sequences are then localized to chromosomeposition using the public human genome sequence database(www.ncbi.nlm.nih.gov:80/cgi-bin/Entrez/hum_srch?chr=hum_chr.inf&query).Genes and gene density in the vicinity of the fragment sequence arerecorded from the genome sequence annotation. Transcriptional activityof those genes is determined from public databases of DNA microarray(arrays.rockefeller.edu/xenopus/inks.html) and SAGE (Serial Analysis ofGene Expression; bioinfo.amc.uva.nl/HTM-bin/index.cgi) data.

Once positional information on STAR sequences is compiled, the data areanalyzed in terms of underlying consensus sequences. Consensus sequencesor trends (understood by this are local areas rich in particularnucleotide combinations, e.g., rich in C and G bases) are detected usingsimilarity search algorithms such as ClustalW (Higgins et al., 1996) andblosum similarity scoring (Altschul and Gish, 1996). Any underlyingconsensuses or trends found are then used to identify other potentialSTARs on a genome scale by performing BLAST searches (Altschul et al.,1990).

Previous research has identified transcriptional regulatory proteinsthat bind to known insulators and boundary elements (Gaszner et al.,1999; Gerasimova and Corces, 1998). In the described examples, theprotein binding sites coincide with DNase I hypersensitive sites whichare essential for insulator or boundary function. The hypothesis thatSTAR elements are also bound by known regulatory proteins is examined bysearching the TRANSFAC database of transcription factors(transfac.gbf.de/TRANSFAC/) for sequence motifs that occur in the STARelements. Sequence motifs that are common among the members of the STARcollections are indicators that the corresponding transcription factorbinds to that element.

Minimal essential sequence: Using this sequence knowledge STAR elementsare truncated and tested for functionality. This is done using thepolymerase chain reaction (PCR) to clone sub-fragments of theSTAR-containing fragments into pSelect by standard techniques (Sambrooket al., 1989). The plasmids containing the sub-fragments are transfectedinto U-2 OS cells and tested for functionality by assaying forantibiotic resistance.

Directionality: The STAR elements are tested for their directionalityusing the pSelect plasmid. For example, the direction of STAR elementsisolated by the pSelect screen is referred to as 5′3′ orientation. Theorientation of the element is reversed by conventional recombinant DNAtechniques (Sambrook et al., 1989). The resulting plasmids aretransfected into the U-2 OS cell line and expression of the reportergene is assayed (Bierhuizen et al., 1997; Himes and Shannon, 2000). Thelevel of expression from the plasmid with the reverse-orientationelement is compared to that with the 5′3′ orientation. If thereverse-orientation plasmid has similar expression levels, then the STARelement does not display directionality.

Combinations and multiples of elements: To determine whether STARelements are able to function in mixed pairs, different elements arecombined and tested. The analysis is performed in the pSDH plasmid byinserting one STAR element in MCSI and a different STAR in MCSII byrecombinant DNA techniques (Sambrook et al., 1989). The resultingplasmids are transfected, and the expression of the reporter gene isassayed (Bierhuizen et al., 1997; Himes and Shannon, 2000); the resultsare compared with the expression from plasmids containing the sameelement at MCSI and MCSII; if the expression is similar for the twotypes of plasmids, then it is concluded that different STAR elements donot interfere with each other.

The strength of single STAR elements is compared with tandem repeats ofelements. This is done by concatamerization of the STAR elements ofinterest with DNA ligase and insertion of the ligation product into thepSDH plasmid by recombinant DNA techniques (Sambrook et al., 1989). Theresulting plasmids are transfected into U-2 OS cells, and the expressionof the reporter gene is assayed (Bierhuizen et al., 1997; Himes andShannon, 2000); the results are compared with the expression fromplasmids containing single STAR elements.

Example 4 Determination of the Distance Over which a STAR Functions

Background: STAR elements are used to optimize expression of single andmultiple transgenes. To determine if a single pair of STAR elements canprotect large or multiple transgenes from silencing it is necessary todetermine the range over which STAR elements act.

Protocol: STAR elements are tested for their functionality over distanceusing derivative plasmids based on pSelect, as follows. A library ofrandom DNA fragments from 500 bp to 10 kb is assembled by standard DNAcloning techniques (Sambrook et al., 1989). Fragments are selected fromthis library that do not possess STAR activity, by testing in thepSelect plasmid as described above. For STAR elements, these fragmentsare inserted between the cloning site and the promoter of the reportergene in the appropriate pSelect plasmid (FIG. 1). This set of plasmidsis transfected into the U-2 OS cell line, and expression measured asdescribed above. The strength of reporter gene expression is correlatedwith the length of the random DNA fragment separating the STAR elementfrom the promoter.

Example 5 Determination of the Maximal Length of STAR Elements

Background: STAR elements are cloned as fragments of DNA recovered usingthe pSelect plasmid, which is done with genomic DNA fragments less than2 kb. However, these might be portions of a more extended STAR element.Extended STAR activity is examined by the following experiments.

Protocol: STAR elements cloned in pSelect are mapped to the human genomesequence. In order to determine if they are portions of a more extendedSTAR element, regions of 4 kb that encompass the clones are amplified byPCR and cloned into the pSelect and/or pSDH plasmid by standardrecombinant DNA techniques (Sambrook et al., 1989). The resultingplasmids are transfected into U-2 OS cells and assayed for reporter geneexpression as described above; plasmids containing the original 2 kbSTAR element are included as a control. Three possible results can beexpected: (1) similar expression by the control and extended STARisolates, demonstrating that the STAR element is confined to theoriginal 2 kb fragment; (2) lower expression by the extended STARisolates, suggesting that the STAR element is contained within the 2 kbfragment and does not act effectively over a distance or that theextended fragment contains an element with a gene transcriptionrepressing quality; (3) higher expression by the extended STAR isolates,suggesting that the extended region contains a more complete STARelement. In the case of result (3), the exercise is reiterated with alarger PCR fragment of 6 kb.

A STAR element may also be a composite of sites to which variousproteins bind. Therefore large DNA fragments with STAR activity could bedivisible into smaller fragments with STAR activity (see example 3).Elements that are greater than 2 kb are recognized as STAR elements ifthey still display STAR activity after truncation to less than 2 kb(including by internal deletion).

Example 6 Methylation and Histone Acetylation States of STAR Elementsand of the Adjacent Transgenes

Background: The regulatory properties of STAR elements are associatedwith the local chromatin structure, which is determined by the DNAitself and by DNA-associated proteins. Changes in chromatin structurethat are associated with changes in gene expression are often producedby secondary modifications of the macromolecules, especially methylationof DNA or acetylation of histone proteins. Identifying the secondarymodifications occurring at STAR elements and at adjacent transgenesprovides hallmarks for these elements.

Protocol: DNA methylation: STAR elements are cloned into the pSelectplasmid by standard techniques (Sambrook et al., 1989). U-2 OS cells arestably transfected with these plasmids, and with pSelect lacking a STARelement as a control to determine basal DNA methylation at the reportergene. Cells are harvested and the chromatin purified by standardprocedures (Thomas, 1998). The DNA is digested with the HpaII and MspIrestriction endonucleases in separate reactions (Sambrook et al., 1989).Both of these restriction enzymes are able to cut the non-methylatedsequence CCGG. When the external C is methylated, both MspI and HpaIIcannot cleave. However, unlike HpaII, MspI can cleave the sequence whenthe internal C is methylated. The DNA is subjected to Southern blottingand the blot is analyzed by indirect end-labeling (Pazin and Kadonaga,1998). As a control, the corresponding pSelect plasmid as naked,unmethylated DNA, is also cut with the described enzymes and subjectedto Southern blotting. Comparison of the different sizes of the DNAfragments reveals whether the DNA is methylated in vivo or not.

Histone acetylation: The same transfected cell lines used for DNAmethylation analysis are used for these experiments. The methoddescribed below yields a high resolution map of the histone acetylationpattern on the STAR elements and the reporter gene (Litt et al., 2001).Micrococcal nuclease digests of nuclei are fractionated on sucrosegradients, and purified nucleosome monomers and dimers are enriched foracetylated histones by immunoprecipitation with anti-acetylhistoneantibodies. The nucleosome fraction and immunoprecipitates are subjectedto analysis, for example by real-time PCR (Jung et al., 2000) usingprimers and a Taqman probe that anneal to the reporter gene or to theSTAR element to yield 0.2 kb products, with a moving window of 0.1 kb.The rate of increase of the Taqman probe fluorescent signal during thePCR (which is proportional to the abundance of the template DNA in thesample) is then measured. The ratio of the abundance of the template DNAin the nucleosome fraction and the immunoprecipitates provides afine-map of the pattern of histone acetylation for each 0.1 kb on thereporter gene and STAR element (or on the reporter gene in the absenceof an element).

Example 7 In vivo Nucleosome Positioning and DNAse I HypersensitiveSites

Background: Chromatin is comprised of DNA, histones, and non-histoneproteins. The histones form a core particle that is wrapped by ˜150 bpof DNA to make a nucleosome. Nucleosomes are separated by 50-75 bp oflinker DNA. Stably positioned nucleosomes on chromosomal DNA repressgene expression, and factors that exclude nucleosomes or otherwiseremodel chromatin can overcome this repression. The positioning ofnucleosomes in a chromosomal region is analyzed by micrococcal nuclease(MNase) assay; MNase cuts chromatin preferentially in the linker DNA.Similarly, some areas of DNA are constitutively exposed to non-histoneproteins, and these are frequently regulatory regions, i.e. sites wherecis-acting regulatory factors bind. Experimentally, these site arehypersensitive to digestion by the enzyme DNase I.

Protocol: To determine the position of nucleosomes on the reporter geneand on the STAR elements, MNase is used (Saluz and Jost, 1993). Nucleiare purified from cultured U-2 OS cells and digested with MNase asdescribed above (histone acetylation). To search for DNase Ihypersensitive sites in the STAR elements or the reporter gene, purifiednuclei are treated with DNase I at an appropriate concentration (e.g.,100 μg/ml genomic DNA and 20-100 U/ml DNaseI), as described (Wallrath etal., 1998). Naked DNA is digested with DNase I as a control. For bothtechniques, the reporter gene and STAR elements are fine-mapped usingprimer extension or indirect end-labeling and Southern blotting, asdescribed (Tanaka et al., 1996; van der Vlag et al., 2000). The MNaseassay reveals a ladder of discrete bands on an autoradiogramcorresponding to the positions of nucleosomes on the STAR elements orthe reporter gene. DNase I hypersensitive sites are manifested asdiscrete bands in the resulting autoradiogram that are absent or lessprominent in the naked DNA control.

Example 8 Cell-type, Tissue Dependence, and Promoter Dependence of STARElements

Background: It has been reported that some insulators or boundaryelements may display tissue specificity (Takada et al., 2000). STARelements have many features in common with insulators and boundaryelements. Both promiscuous and tissue-specific STAR elements havebiotechnological value in transgenic applications. The assay describedbelow is performed to assess cell-type dependence. Cell and tissuespecificity of the elements are examined further by examining theexpression of genes in the vicinity of the elements in the human genome,using public databases of DNA microarray(arrays.rockefeller.edu/xenopus/links.html) and SAGE (Serial Analysis ofGene Expression; bioinfo.amc.uva.nl/HTM-bin/index.cgi) data.

Protocol: STAR elements are tested in the pSDH plasmid. Three cell linesare transfected using standard protocols: the human U-2 OS osteosarcomacell line (Heldin et al., 1986), the Vero cell line from African greenmonkey kidney (Simizu et al., 1967), and the CHO cell line from Chinesehamster ovary (Kao and Puck, 1968). Elements able to function in allthree cell types are categorized as promiscuous. Those only displayingactivity in one or two of the cell-lines are categorized as restrictedin their cell-type functionality.

Promoter specificity: STAR elements are currently selected and tested inthe context of function with two promoters, the entire cytomegalovirus(CMV) promoter or the Tetracycline Response Element and minimal CMVpromoter (in combination with the tTA transcriptional activator). Toassess promoter specificity, STAR function is tested with other commonlyused viral promoters, namely the simian virus type 40 (SV40) early andlate promoters, the adenoviral EIA and major late promoters, and theRous sarcoma virus (RSV) long terminal repeat (Doll et al., 1996; Smithet al., 2000; Weaver and Kadan, 2000; Xu et al., 1995). Each of thesepromoters is cloned separately into the pSelect plasmid by standardtechniques (Sambrook et al., 1989) along with STAR elements. Theresulting plasmids are transfected into the U-2 OS cell line and assayedfor reporter gene expression, as described above. The ability of STARelements to protect against silencing, is determined by comparison withplasmids lacking STAR elements.

Example 9 Methods for Improvement of STAR Elements

Background: Improved STAR elements are developed. Improvements yieldincreased strength of anti-repressive activity, and elements withinducible and tissue-specific activity. These improvements are made by acombination of techniques.

Protocols: Forced evolution: Error prone PCR (Cherry et al., 1999; Henkeand Bomscheuer, 1999) is used to introduce an average of one to twopoint mutations per element. The mutagenized elements are screened usingpSelect plasmids containing reporter-selectable marker fusion proteinsby for example fluorescence activated cell sorting and antibioticresistance (Bennett et al., 1998). Subsequent rounds of error prone PCRand selection are carried out to derive elements with furtherimprovements in activity.

Tandem and heterologous combinations: As described above, tandem andheterologous combinations of elements are tested for activity incomparison with the single elements (example 3).

The relative dominance of STAR elements is tested on a case by casebasis. It is used to test the strength of an element; for example, if anew STAR element is dominant to a known, strong element with a genetranscription repressing quality, then the STAR is classified as verystrong. The possibility that the dominance relationship between a STARand an element with a gene transcription repressing quality is celltype-, tissue-, or promoter-specific is also considered (example 8). Thedominance test utilizes the pSelect plasmid, with individual elementswith a gene transcription repressing quality placed upstream ofindividual STAR elements by standard recombinant DNA techniques(Sambrook et al., 1989). The plasmids are transfected to U-2 OS cellsand reporter gene expression is assayed. STAR dominance is manifested byhigher expression than the plasmid with only an element with a genetranscription repressing quality.

Introduction of binding sites for other DNA-binding proteins to STARelements to add novel characteristics (e.g., inducibility, tissuespecificity)

Background: Regulatable STAR elements are created by combining them withbinding sites for signal-dependent DNA binding proteins. In one examplethis would involve juxtaposition of a STAR and a glucocorticoid responseelement (GRE). In the absence of glucocorticoid stimulation the STARelement would function as described. Upon stimulation, the naturallyoccurring glucocorticoid receptor binds to the GRE and interferes withSTAR function.

Protocol: Using conventional DNA cloning (Sambrook et al., 1989), a GREis introduced into the pSelect vector adjacent to STAR elements. Theplasmid is transfected into U-2 OS cells as described above. Cells aredivided into two cultures; one is treated with glucocorticoid (10 μM).Expression of the reporter gene is measured and compared between the twocultures. Differences in expression demonstrate the ability to regulateSTAR function by action of a signal-dependent DNA-binding protein.

Promiscuous STAR elements: Testing or enhancing these characteristicsinvolves cultivation in different cell lines, and long term cultivationwithout antibiotic selection (examples 8 and 10).

Example 10 STAR Elements Obviate the Need for Continuous Selection forMaintenance of the Transgene

Background: In transgenesis, reliance on selection markers has twodrawbacks: the selection agent is usually expensive and carries ametabolic cost to the cells, and there are regulatory and ethicalobjections to including selectable markers in transgenic applications,especially if the transgene itself is in the product (e.g., crop plants,gene therapy vectors). STAR elements reduce or eliminate the need tomaintain selection after establishing the transgenic isolate.Consequently, the resistance gene can be removed from the transgenicgenome by site-specific recombination with diminished loss of transgeneexpression.

Protocol: Stably transfected U-2 OS cell lines containingchromosomally-integrated STAR elements flanking reporter genes areproduced by co-transfection of the pSDH plasmid with a trans-actingantibiotic resistance plasmid as described above. The experimentinvolves testing the stability of the reporter gene expression level inthese cell lines during prolonged (3-6 month) cultivation in the absenceof selection. This is tested with STAR elements flanking the luciferaseor GFP reporter genes in pSDH plasmids.

The antibiotic resistance gene is removed by constructing an expressionplasmid (based on pSDH) in which the antibiotic selection marker isflanked by recombinase target sites. The selectable marker issubsequently excised by recombinase activity, as described above(example 2).

Example 11 Predictability and Yield are Improved by Application of STARElements in Expression Systems

STAR elements function to block the effect of transcriptional repressioninfluences on transgene expression units. These repression influencescan be due to heterochromatin (“position effects”, (Boivin & Dura,1998)) or to adjacent copies of the transgene (“repeat-induced genesilencing”, (Garrick et al., 1998)). Two of the benefits of STARelements for heterologous protein production are increasedpredictability of finding high-expressing primary recombinant hostcells, and increased yield during production cycles. These benefits areillustrated in this example.

Materials and Methods: Construction of the pSDH vectors andSTAR-containing derivatives: The pSDH-Tet vector was constructed bypolymerase chain reaction amplification (PCR) of the luciferase openreading frame from plasmid pREP4-HSF-Luc (van der Vlag et al., 2000)using primers C67 and C68 (all PCR primers and mutagenicoligonucleotides are listed in Table 4), and insertion of theSacII/BamHI fragment into SacII/BamHI-digested pUHD10-3 (Gossen &Bujard, 1992). The luciferase expression unit was re-amplified withprimers C65 and C66, and re-inserted into pUHD10-3 in order to flank itwith two multiple cloning sites (MCSI and MCSII). An AscI site was thenintroduced into MCSI by digestion with EcoRI and insertion of a linker(comprised of annealed oligonucleotides D93 and D94). The CMV promoterwas amplified from plasmid pCMV-Bsd (Invitrogen K510-01) with primersD90 and D91, and used to replace the Tet-Off promoter in pSDH-Tet bySalI/SacII digestion and ligation to create vector pSDH-CMV. Theluciferase open reading frame in this vector was replaced by SEAP(Secreted Alkaline Phosphatase) as follows: vector pSDH-CMV was digestedwith SacII and BamHI and made blunt; the SEAP open reading frame wasisolated from pSEAP-basic (Clontech 6037-1) by EcoRI/SalI digestion,made blunt and ligated into pSDH-CMV to create vector pSDH-CS. Thepuromycin resistance gene under control of the SV40 promoter wasisolated from plasmid pBabe-Puro (Morgenstern & Land, 1990) by PCR,using primers C81 and C82. This was ligated into vector pGL3-control(BamHI site removed) (Promega E1741) digested with NcoI/XbaI, to createpGL3-puro. pGL3-puro was digested with BglII/SalI to isolate theSV40-puro resistance gene, which was made blunt and ligated into NheIdigested, blunt-ended pSDH-CS. The resulting vector, pSDH-CSP, is shownin FIG. 6. All cloning steps were carried out following the instructionsprovided by the manufacturers of the reagents, according to methodsknown in the art (Sambrook et al., 1989).

STAR elements were inserted into MCSI and MCSII in two steps, bydigestion of the STAR element and the pSDH-CSP vector with anappropriate restriction enzyme, followed by ligation. The orientation ofSTAR elements in recombinant pSDH vectors was determined by restrictionmapping. The identity and orientation of the inserts were verified byDNA sequence analysis. Sequencing was performed by the dideoxy method(Sanger et al., 1977) using a Beckman CEQ2000 automated DNA sequencer,according to the manufacturer's instructions. Briefly, DNA was purifiedfrom E. coli using QIAPREP® Spin Miniprep and Plasmid Midi Kits (QIAGEN27106 and 12145, respectively). Cycle sequencing was carried out usingcustom oligonucleotides C85, E25, and E42 (Table 4), in the presence ofdye terminators (CEQ Dye Terminator Cycle Sequencing Kit, Beckman608000).

Transfection and culture of CHO cells with pSDH plasmids: The ChineseHamster Ovary cell line CHO-K1 (ATCC CCL-61) was cultured in HAMS-F12medium +10% Fetal Calf Serum containing 2 mM glutamine, 100 U/mlpenicillin, and 100 micrograms/ml streptomycin at 37° C./5% CO2. Cellswere transfected with the pSDH-CSP vector, and its derivativescontaining STAR6 or STAR49 in MCSI and MCSII, using SUPERFECT®Transfection Reagent (QIAGEN®) as described by the manufacturer.Briefly, cells were seeded to culture vessels and grown overnight to70-90% confluence. SUPERFECT® reagent was combined with plasmid DNA(linearized in this example by digestion with PvuI) at a ratio of 6microliters per microgram (e.g., for a 10 cm Petri dish, 20 microgramsDNA and 120 microliters SUPERFECT®) and added to the cells. Afterovernight incubation the transfection mixture was replaced with freshmedium, and the transfected cells were incubated further. Afterovernight cultivation, 5 micrograms/ml puromycin was added. Puromycinselection was complete in 2 weeks, after which time individual puromycinresistant CHO/pSDH-CSP clones were isolated at random and culturedfurther.

Secreted Alkaline Phosphatase (SEAP) assay: SEAP activity (Berger etal., 1988, Henthorn et al., 1988, Kain, 1997, Yang et al., 1997) in theculture medium of CHO/pSDH-CSP clones was determined as described by themanufacturer (Clontech Great EscAPe kit #K2041). Briefly, an aliquot ofmedium was heat inactivated at 65° C., then combined with assay bufferand CSPD chemiluminescent substrate and incubated at room temperaturefor 10 minutes. The rate of substrate conversion was then determined ina luminometer (Turner 20/20TD). Cell density was determined by countingtrypsinized cells in a COULTER® ACT10 cell counter.

Transfection and culture of U-2 OS cells with pSDH plasmids: The humanosteosarcoma U-2 OS cell line (ATCC #HTB-96) was cultured in Dulbecco'sModified Eagle Medium +10% Fetal Calf Serum containing glutamine,penicillin, and streptomycin (supra) at 37° C./5% CO2. Cells wereco-transfected with the pSDH-CMV vector, and its derivatives containingSTAR6 or STAR8 in MCSI and MCSII, (along with plasmid pBabe-Puro) usingSUPERFECT® Transfection Reagent (supra). Puromycin selection wascomplete in 2 weeks, after which time individual puromycin resistant U-2OS/pSDH-CMV clones were isolated at random and cultured further.

Luciferase assay: Luciferase activity (Himes & Shannon, 2000) wasassayed in resuspended cells according to the instructions of the assaykit manufacturer (Roche 1669893), using a luminometer (Turner 20/20TD).Total cellular protein concentration was determined by the bicinchoninicacid method according to the manufacturer's instructions (Sigma B-9643),and used to normalize the luciferase data.

Results: Recombinant CHO cell clones containing the pSDH-CSP vector, orpSDH-CSP plasmids containing STAR6 or STAR49 (Table 5), were culturedfor 3 weeks. The SEAP activity in the culture supernatants was thendetermined, and is expressed on the basis of cell number (FIG. 7). Ascan be seen, clones with STAR elements in the expression units wereisolated that express 2-3 fold higher SEAP activity than clones whoseexpression units do not include STAR elements. Furthermore, the numberof STAR-containing clones that express SEAP activity at or above themaximal activity of the STAR-less clones is quite high: 25% to 40% ofthe STAR clone populations exceed the highest SEAP expression of thepSDH-CSP clones.

Recombinant U-2 OS cell clones containing the pSDH-CMV vector, orpSDH-CMV plasmids containing STAR6 or STAR8 (Table 5), were cultured for3 weeks. The luciferase activity in the host cells was then determined,and is expressed as relative luciferase units (FIG. 8), normalized tototal cell protein. The recombinant U-2 OS clones with STAR elementsflanking the expression units had higher yields than the STAR-lessclones: the highest expression observed from STAR8 clones was 2-3 foldhigher than the expression from STAR-less clones. STAR6 clones hadmaximal expression levels 5 fold higher than the STAR-less clones. TheSTAR elements conferred greater predictability as well: for both STARelements, 15 to 20% of the clones displayed luciferase expression atlevels comparable to or greater than the STAR-less clone with thehighest expression level.

These results demonstrate that, when used with the strong CMV promoter,STAR elements increase the yield of heterologous proteins (luciferaseand SEAP). All three of the STAR elements introduced in this exampleprovide elevated yields. The increased predictability conferred by theSTAR elements is manifested by the large proportion of the clones withyields equal to or greater than the highest yields displayed by theSTAR-less clones.

Example 12 STAR Elements Improve the Stability of Transgene Expression

During cultivation of recombinant host cells, it is common practice tomaintain antibiotic selection. This is intended to preventtranscriptional silencing of the transgene, or loss of the transgenefrom the genome by processes such as recombination. However it isundesirable for production of heterologous proteins, for a number ofreasons. First, the antibiotics that are used are quite expensive, andcontribute significantly to the unit cost of the product. Second, forbiopharmaceutical use, the protein must be demonstrably pure, with notraces of the antibiotic in the product. One advantage of STAR elementsfor heterologous protein production is that they confer stableexpression on transgenes during prolonged cultivation, even in theabsence of antibiotic selection; this property is demonstrated in thisexample.

Materials and Methods: The U-2 OS cell line was transfected with theplasmid pSDH-Tet-STAR6 and cultivated as described in Example 11.Individual puromycin-resistant clones were isolated and cultivatedfurther in the absence of doxycycline. At weekly intervals the cellswere transferred to fresh culture vessels at a dilution of 1:20.Luciferase activity was measured at periodic intervals as described inExample 11. After 15 weeks the cultures were divided into tworeplicates; one replicate continued to receive puromycin, while theother replicate received no antibiotic for the remainder of theexperiment (25 weeks total).

Results: Table 6 presents the data on luciferase expression by anexpression unit flanked with STAR6 during prolonged growth with orwithout antibiotic. As can be seen, the expression of the reportertransgene, luciferase, remains stable in the U-2 OS host cells for theduration of the experiment. After the cultures were divided into twotreatments (plus antibiotic and without antibiotic) the expression ofluciferase was essentially stable in the absence of antibioticselection. This demonstrates the ability of STAR elements to protecttransgenes from silencing or loss during prolonged cultivation. It alsodemonstrates that this property is independent of antibiotic selection.Therefore production of heterologous proteins is possible withoutincurring the costs of the antibiotic or of difficult downstreamprocessing.

Example 13 Minimal Essential Sequences of STAR Elements

STAR elements are isolated from the genetic screen described inExample 1. The screen uses libraries constructed with human genomic DNAthat was size-fractionated to approximately 0.5-2 kilobases (supra). TheSTAR elements range from 500 to 2361 base pairs (Table 5). It is likelythat, for many of the STAR elements that have been isolated, STARactivity is conferred by a smaller DNA fragment than the initiallyisolated clone. It is useful to determine these minimum fragment sizesthat are essential for STAR activity, for two reasons. First, smallerfunctional STAR elements would be advantageous in the design of compactexpression vectors, since smaller vectors transfect host cells withhigher efficiency. Second, determining minimum essential STAR sequencespermits the modification of those sequences for enhanced functionality.Two STAR elements have been fine-mapped to determine their minimalessential sequences.

Materials and Methods: STAR10 (1167 base pairs) and STAR27 (1520 basepairs) have been fine-mapped. They have been amplified by PCR to yieldsub-fragments of approximately equal length (FIG. 9 legend). For initialtesting, these have been cloned into the pSelect vector at the BamHIsite, and transfected into U-2 OS/Tet-Off/LexA-HP1 cells as described inExample 1. After selection for hygromycin resistance, LexA-HP1 wasinduced by lowering the doxycycline concentration. Transfected cellswere then incubated with Zeocin to test the ability of the STARfragments to protect the SV40-Zeo expression unit from repression due toLexA-HP1 binding.

Results: In this experiment STAR10 and STAR 27 confer good protectionagainst gene silencing, as expected (FIG. 9). This is manifested byrobust growth in the presence of Zeocin.

Of the 3 STAR10 sub-fragments, 10A (˜400 base pairs) confers ontransfected cells vigorous growth in the presence of Zeocin, exceedingthat of the full-length STAR element. Cells transfected with pSelectconstructs containing the other 2 sub-fragments do not grow in thepresence of Zeocin. These results identify the ˜400 base pair 10Afragment as encompassing the DNA sequence responsible for theanti-repression activity of STAR10.

STAR27 confers moderate growth in Zeocin to transfected cells in thisexperiment (FIG. 9). One of the sub-fragments of this STAR, 27B (˜500base pairs), permits weak growth of the host cells in Zeocin-containingmedium. This suggests that the anti-repression activity of this STAR ispartially localized on sub-fragment 27B, but full activity requiressequences from 27A and/or 27C (each ˜500 base pairs) as well.

Example 14 STAR Elements Function in Diverse Strains of CulturedMammalian Cells

The choice of host cell line for heterologous protein expression is acritical parameter for the quality, yield, and unit cost of the protein.Considerations such as post-translational modifications, secretorypathway capacity, and cell line immortality dictate the appropriate cellline for a particular biopharmaceutical production system. For thisreason, the advantages provided by STAR elements in terms of yield,predictability, and stability should be obtainable in diverse celllines. This was tested by comparing the function of STAR6 in the humanU-2 OS cell line in which it was originally cloned, and the CHO cellline which is widely applied in biotechnology.

Materials and Methods: The experiments of Example 11 are referred to.

Results: The expression of the SEAP reporter gene in CHO cells ispresented in FIG. 7; the expression of the luciferase reporter gene inU-2 OS cells is presented in FIG. 8. By comparison of the results ofthese two experiments, it is apparent that the STAR6 element isfunctional in both cell lines: reporter gene expression was morepredictable in both of them, and clones of each cell line displayedhigher yields, when the reporter gene was shielded from position effectsby STAR6. These two cell lines are derived from different species (humanand hamster) and different tissue types (bone and ovary), reflecting thebroad range of host cells in which this STAR element can be utilized inimproving heterologous protein expression.

Example 15 STAR Elements Function in the Context of VariousTranscriptional Promoters

Transgene transcription is achieved by placing the transgene openreading frame under control of an exogenous promoter. The choice ofpromoter is influenced by the nature of the heterologous protein and theproduction system. In most cases, strong constitutive promoters arepreferred because of the high yields they can provide. Some viralpromoters have these properties; the promoter/enhancer of thecytomegalovirus immediate early gene (“CMV promoter”) is generallyregarded as the strongest promoter in common biotechnological use(Boshart et al., 1985, Doll et al., 1996, Foecking & Hofstetter, 1986).The simian virus SV40 promoter is also moderately strong (Boshart etal., 1985, Foecking & Hofstetter, 1986) and is frequently used forectopic expression in mammalian cell vectors. The Tet-Off promoter isinducible: the promoter is repressed in the presence of tetracycline orrelated antibiotics (doxycycline is commonly used) in cell-lines whichexpress the tTA plasmid (Clontech K1620-A), and removal of theantibiotic results in transcriptional induction (Deuschle et al., 1995,Gossen & Bujard, 1992, Izumi & Gilbert, 1999, Umana et al., 1999).

Materials and Methods: The construction of the pSDH-Tet and pSDH-CMVvectors is described in Example 11. pSDH-SV40 was constructed by PCRamplification of the SV40 promoter (primers D41 and D42) from plasmidpSelect-SV40-Zeo (Example 1), followed by digestion of the PCR productwith SacII and SalI. The pSDH-CMV vector was digested with SacII andSalI to remove the CMV promoter, and the vector and SV40 fragment wereligated together to create pSDH-SV40. STAR6 was cloned into MCSI andMCSII as described in Example 11. The plasmids pSDH-Tet, pSDH-Tet-STAR6,pSDH-Tet-STAR7, pSDH-SV40 and pSDH-SV40-STAR6 were co-transfected withpBabe-Puro into U-2 OS using SUPERFECT® Transfection Reagent asdescribed by the manufacturer. Cell cultivation, puromycin selection,and luciferase assays were carried out as described in Example 11.

Results: FIGS. 8, 10, and 11 compare the expression of the luciferasereporter gene from 3 different promoters: two strong and constitutiveviral promoters (CMV and SV40), and the inducible Tet-Off promoter. Allthree promoters were tested in the context of the STAR6 element in U-2OS cells. The results demonstrate that the yield and predictability fromall 3 promoters are increased by STAR6. As described in Examples 11 and14, STAR6 is beneficial in the context of the CMV promoter (FIG. 8).Similar improvements are seen in the context of the SV40 promoter (FIG.10): the yield from the highest-expressing STAR6 clone is 2-3 foldgreater than the best pSDH-SV40 clones, and 6 STAR clones (20% of thepopulation) have yields higher than the best STAR-less clones. In thecontext of the Tet-Off promoter under inducing (low doxycycline)concentrations, STAR6 also improves the yield and predictability oftransgene expression (FIG. 11): the highest-expressing STAR6 clone has a20-fold higher yield than the best pSDH-Tet clone, and 9 STAR6 clones(35% of the population) have yields higher than the best STAR-lessclone. It is concluded that this STAR element is versatile in itstransgene-protecting properties, since it functions in the context ofvarious biotechnologically useful promoters of transcription.

Example 16 STAR Element Function can be Directional

While short nucleic acid sequences can be symmetrical (e.g.,palindromic), longer naturally-occurring sequences are typicallyasymmetrical. As a result, the information content of nucleic acidsequences is directional, and the sequences themselves can be describedwith respect to their 5′ and 3′ ends. The directionality of nucleic acidsequence information affects the arrangement in which recombinant DNAmolecules are assembled using standard cloning techniques known in theart (Sambrook et al., 1989). STAR elements are long, asymmetrical DNAsequences, and have a directionality based on the orientation in whichthey were originally cloned in the pSelect vector. In the examples givenabove, using two STAR elements in pSDH vectors, this directionality waspreserved. This orientation is described as the native or 5′-3′orientation, relative to the Zeocin resistance gene (see FIG. 12). Inthis example the importance of directionality for STAR function istested in the pSDH-Tet vector. Since the reporter genes in the pSDHvectors are flanked on both sides by copies of the STAR element ofinterest, the orientation of each STAR copy must be considered. Thisexample compares the native orientation with the opposite orientation(FIG. 12).

Materials and Methods: The STAR66 element was cloned into pSDH-Tet asdescribed in Example 11. U-2 OS cells were co-transfected with plasmidspSDH-Tet-STAR66-native and pSDH-Tet-STAR66-opposite, and cultivated asdescribed in Example 11. Individual clones were isolated and cultivated;the level of luciferase expression was determined as described (supra).

Results: The results of the comparison of STAR66 activity in the nativeorientation and the opposite orientation are shown in FIG. 13. WhenSTAR66 is in the opposite orientation, the yield of only one clone isreasonably high (60 luciferase units). In contrast, the yield of thehighest-expressing clone when STAR66 is in the native orientation isconsiderably higher (100 luciferase units), and the predictability ismuch higher as well: 7 clones of the native-orientation population (30%)express luciferase above the level of the highest-expressing clone fromthe opposite-orientation population, and 15 of the clones in thenative-orientation population (60%) express luciferase above 10 relativeluciferase units. Therefore it is demonstrated that STAR66 function isdirectional.

Example 17 Transgene Expression in the Context of STAR Elements is CopyNumber-dependent

Transgene expression units for heterologous protein expression aregenerally integrated into the genome of the host cell to ensure stableretention during cell division. Integration can result in one ormultiple copies of the expression unit being inserted into the genome;multiple copies may or may not be present as tandem arrays. Theincreased yield demonstrated for transgenes protected by STAR elements(supra) suggests that STAR elements are able to permit the transgeneexpression units to function independently of influences ontranscription associated with the site of integration in the genome(independence from position effects (Boivin & Dura, 1998)). It suggestsfurther that the STAR elements permit each expression unit to functionindependently of neighboring copies of the expression unit when they areintegrated as a tandem array (independence from repeat-induced genesilencing (Garrick et al., 1998)). Copy number-dependence is determinedfrom the relationship between transgene expression levels and copynumber, as described in the example below.

Materials and Methods: U-2 OS cells were co-transfected withpSDH-Tet-STAR10 and cultivated under puromycin selection as described(supra). Eight individual clones were isolated and cultivated further.Then cells were harvested, and one portion was assayed for luciferaseactivity as described (supra). The remaining cells were lysed and thegenomic DNA purified using the DNEASY® Tissue Kit (QIAGEN®69504) asdescribed by the manufacturer. DNA samples were quantitated by UVspectrophotometry. Three micrograms of each genomic DNA sample weredigested with PvuII and XhoI overnight as described by the manufacturer(New England Biolabs), and resolved by agarose gel electrophoresis. DNAfragments were transferred to a nylon membrane as described (Sambrook etal., 1989), and hybridized with a radioactively labeled probe to theluciferase gene (isolated from BamHI/SacII-digested pSDH-Tet). The blotwas washed as described (Sambrook et al., 1989) and exposed to aphosphorimager screen (Personal F/X, BioRad). The resultingautoradiogram (FIG. 14) was analyzed by densitometry to determine therelative strength of the luciferase DNA bands, which represents thetransgene copy number.

Results: The enzyme activities and copy numbers (DNA band intensities)of luciferase in the clones from the pSDH-Tet-STAR10 clone population isshown in FIG. 15. The transgene copy number is highly correlated withthe level of luciferase expression in these pSDH-Tet-STAR10 clones(r=0.86). This suggests that STAR10 confers copy number-dependence onthe transgene expression units, making transgene expression independentof other transgene copies in tandem arrays, and independent ofgene-silencing influences at the site of integration.

Example 18 STAR Elements Function as Enhancer Blockers but not Enhancers

Gene promoters are subject to both positive and negative influences ontheir ability to initiate transcription. An important class of elementsthat exert positive influences are enhancers. Enhancers arecharacteristically able to affect promoters even when they are locatedfar away (many kilobase pairs) from the promoter. Negative influencesthat act by heterochromatin formation (e.g., Polycomb group proteins)have been described above, and these are the target of STAR activity.The biochemical basis for enhancer function and for heterochromatinformation is fundamentally similar, since they both involve binding ofproteins to DNA. Therefore it is important to determine whether STARelements are able to block positive influences as well as negativeinfluences, in other words, to shield transgenes from genomic enhancersin the vicinity of the site of integration. The ability to shieldtransgenes from enhancer activity ensures stable and predictableperformance of transgenes in biotechnological applications. This exampleexamines the performance of STAR elements in an enhancer-blocking assay.

Another feature of STAR activity that is important to their function isthe increased yield they confer on transgenes (Example 11). STARs areisolated on the basis of their ability to maintain high levels of Zeocinexpression when heterochromatin-forming proteins are bound adjacent tothe candidate STAR elements. High expression is predicted to occurbecause STARs are anticipated to block the spread of heterochromatininto the Zeocin expression unit. However, a second scenario is that theDNA fragments in Zeocin-resistant clones contain enhancers. Enhancershave been demonstrated to have the ability to overcome the repressiveeffects of Polycomb-group proteins such as those used in the method ofthe STAR screen (Zink & Paro, 1995). Enhancers isolated by thisphenomenon would be considered false positives, since enhancers do nothave the properties claimed here for STARs. In order to demonstrate thatSTAR elements are not enhancers, they have been tested in an enhancerassay.

The enhancer-blocking assay and the enhancer assay are methodologicallyand conceptually similar. The assays are shown schematically in FIG. 16.The ability of STAR elements to block enhancers is performed using theE47/E-box enhancer system. The E47 protein is able to activatetranscription by promoters when it is bound to an E-box DNA sequencelocated in the vicinity of those promoters (Quong et al., 2002). E47 isnormally involved in regulation of B and T lymphocyte differentiation(Quong et al., 2002), but it is able to function in diverse cell typeswhen expressed ectopically (Petersson et al., 2002). The E-box is apalindromic DNA sequence, CANNTG (Knofler et al., 2002). In theenhancer-blocking assay, an E-box is placed upstream of a luciferasereporter gene (including a minimal promoter) in an expression vector. Acloning site for STAR elements is placed between the E-box and thepromoter. The E47 protein is encoded on a second plasmid. The assay isperformed by transfecting both the E47 plasmid and the luciferaseexpression vector into cells; the E47 protein is expressed and binds tothe E-box, and the E47/E-box complex is able to act as an enhancer. Whenthe luciferase expression vector does not contain a STAR element, theE47/E-box complex enhances luciferase expression (FIG. 16A, situation1). When STAR elements are inserted between the E-box and the promoter,their ability to block the enhancer is demonstrated by reducedexpression of luciferase activity (FIG. 16A, situation 2); if STARscannot block enhancers, luciferase expression is activated (FIG. 16A,situation 3).

The ability of STAR elements to act as enhancers utilizes the sameluciferase expression vector. In the absence of E47, the E-box itselfdoes not affect transcription. Instead, enhancer behavior by STARelements will result in activation of luciferase transcription. Theassay is performed by transfecting the luciferase expression vectorwithout the E47 plasmid. When the expression vector does not containSTAR elements, luciferase expression is low (FIG. 16B, situation 1). IfSTAR elements do not have enhancer properties, luciferase expression islow when a STAR element is present in the vector (FIG. 16B, situation2). If STAR elements do have enhancer properties, luciferase expressionwill be activated in the STAR-containing vectors (FIG. 16B, situation3).

Materials and Methods: The luciferase expression vector was constructedby inserting the E-box and a human alkaline phosphatase minimal promoterfrom plasmid mu-E5+E2×6-cat(x) (Ruezinsky et al., 1991) upstream of theluciferase gene in plasmid pGL3-basic (Promega E1751), to createpGL3-E-box-luciferase (gift of W. Romanow). The E47 expression plasmidcontains the E47 open reading frame under control of a beta-actinpromoter in the pHBAPr-1-neo plasmid; E47 in constitutively expressedfrom this plasmid (gift of W. Romanow).

STAR elements 1, 2, 3, 6, 10, 11, 18, and 27 have been cloned into theluciferase expression vector. Clones containing the Drosophila scselement and the chicken beta-globin HS4-6× core (“HS4”) element havebeen included as positive controls (they are known to block enhancers,and to have no intrinsic enhancer properties (Chung et al., 1993, Kellum& Schedl, 1992)), and the empty luciferase expression vector has beenincluded as a negative control. All assays were performed using the U-2OS cell line. In the enhancer-blocking assay, the E47 plasmid wasco-transfected with the luciferase expression vectors (empty vector, orcontaining STAR or positive-control elements). In the enhancer assay,the E47 plasmid was co-transfected with STARless luciferase expressionvector as a positive control for enhancer activity; all other samplesreceived a mock plasmid during co-transfection. The transientlytransfected cells were assayed for luciferase activity 48 hours afterplasmid transfection (supra). The luciferase activity expressed from aplasmid containing no E-box or STAR/control elements was subtracted, andthe luciferase activities were normalized to protein content asdescribed (supra).

Results: FIG. 17 shows the results of the enhancer-blocking assay. Inthe absence of STAR elements (or the known enhancer-blocking elementsscs and HS4), the E47/E-box enhancer complex activates expression ofluciferase (“vector”); this enhanced level of expression has beennormalized to 100. Enhancer activity is blocked by all STAR elementstested. Enhancer activity is also blocked by the HS4 and scs elements,as expected (Bell et al., 2001, Gerasimova & Corces, 2001). Theseresults demonstrate that in addition to their ability to block thespreading of transcriptional silencing (negative influences), STARelements are able to block the action of enhancers (positiveinfluences).

FIG. 18 shows the results of the enhancer assay. The level of luciferaseexpression due to enhancement by the E47/E-box complex is set at 100(“E47”). By comparison, none of the STAR elements bring aboutsignificant activation of luciferase expression. As expected, the scsand HS4 elements also do not bring about activation of the reportergene. Therefore it is concluded that at least the tested STAR elementsdo not possess enhancer properties.

Example 20 STAR Elements are Conserved Between Mouse and Human

BLAT analysis of the STAR DNA sequence against the human genome database(genome.ucsc.edu/cgi-bin/hgGateway) reveals that some of these sequenceshave high sequence conservation with other regions of the human genome.These duplicated regions are candidate STAR elements; if they do showSTAR activity, they would be considered paralogs of the cloned STARs(two genes or genetic elements are the to be paralogous if they arederived from a duplication event (Li, 1997)).

BLAST analysis of the human STARs against the mouse genome(www.ensembl.org/Mus_musculus/blastview) also reveals regions of highsequence conservation between mouse and human. This sequenceconservation has been shown for fragments of 15 out of the 65 human STARelements. The conservation ranges from 64% to 89%, over lengths of 141base pairs to 909 base pairs (Table 7). These degrees of sequenceconservation are remarkable and suggest that these DNA sequences mayconfer STAR activity within the mouse genome as well. Some of thesequences from the mouse and human genomes in Table 7 could be strictlydefined as orthologs (two genes or genetic elements are the to beorthologous if they are derived from a speciation event (Li, 1997)). Forexample, STAR6 is between the SLC8 μl and HAAO genes in both the humanand mouse genomes. In other cases, a cloned human STAR has a paralogwithin the human genome, and its ortholog has been identified in themouse genome. For example, STAR3a is a fragment of the 15q11.2 region ofhuman chromosome 15. This region is 96.9% identical (paralogous) with aDNA fragment at 5q33.3 on human chromosome 5, which is near the IL12Binterleukin gene. These human DNAs share approximately 80% identity witha fragment of the 11B2 region on mouse chromosome 11. The 11B2 fragmentis also near the (mouse) IL12B interleukin gene. Therefore STAR3a andthe mouse 11B2 fragment can be strictly defined as paralogs.

In order to test the hypothesis that STAR activity is shared betweenregions of high sequence conservation in the mouse and human genome, oneof the human STARs with a conserved sequence in mouse, STAR18, has beenanalyzed in greater detail. The sequence conservation in the mousegenome detected with the original STAR18 clone extends leftward on humanchromosome 2 for about 500 base pairs (FIG. 19; left and right relate tothe standard description of the arms of chromosome 2). In this examplewe examine whether the region of sequence conservation defines a“naturally occurring” STAR element in human that is more extensive inlength than the original clone. We also examine whether the STARfunction of this STAR element is conserved between mouse and human.

Materials and Methods: The region of mouse/human sequence conservationaround STAR 18 was recovered from human BAC clone RP11-387A1 by PCRamplification, in three fragments: the entire region (primers E93 andE94), the leftward half (primers E93 and E92), and the rightward half(primers E57 and E94). The corresponding fragments from the homologousmouse region were recovered from BAC clone RP23-400H17 in the samefashion (primers E95 and E98, E95 and E96, and E97 and E98,respectively). All fragments were cloned into the pSelect vector andtransfected into a U-2 OS/Tet-Off/LexA-HP1 cell line (supra). Followingtransfection, hygromycin selection was carried out to select fortransfected cells. The LexA-HP1 protein was induced by lowering thedoxycycline concentration, and the ability of the transfected cells towithstand the antibiotic Zeocin (a measure of STAR activity) wasassessed by monitoring cell growth.

Results: The original STAR18 clone was isolated from Sau3AI digestedhuman DNA ligated into the pSelect vector on the basis of its ability toprevent silencing of a Zeocin resistance gene. Alignment of the humanSTAR18 clone (497 base pairs) with the mouse genome revealed highsequence similarity (72%) between the orthologous human and mouse STAR18regions. It also uncovered high similarity (73%) in the region extendingfor 488 base pairs immediately leftwards of the Sau3AI site that definesthe left end of the cloned region (FIG. 19). Outside these regions thesequence similarity between human and mouse DNA drops below 60%.

As indicated in FIG. 19, both the human and the mouse STAR18 elementsconfer survival on Zeocin to host cells expressing the lexA-HP1repressor protein. The original 497 base pair STAR18 clone and its mouseortholog both confer the ability to grow (FIG. 19, a and d). Theadjacent 488 base pair regions of high similarity from both genomes alsoconfer the ability to grow, and in fact their growth phenotype is morevigorous than that of the original STAR18 clone (FIG. 19, b and e). Whenthe entire region of sequence similarity was tested, these DNAs fromboth mouse and human confer growth, and the growth phenotype is morevigorous than the two sub-fragments (FIG. 19, c and f). These resultsdemonstrate that the STAR activity of human STAR18 is conserved in itsortholog from mouse. The high sequence conservation between theseorthologous regions is particularly noteworthy because they are notprotein-coding sequences, leading to the conclusion that they have someregulatory function that has prevented their evolutionary divergencethrough mutation.

This analysis demonstrates that cloned STAR elements identified by theoriginal screening program may in some cases represent partial STARelements, and that analysis of the genomic DNA in which they areembedded can identify sequences with stronger STAR activity.

Example 21

Materials and Methods: Using the genetic screen described in theoriginal patent application, sixty-six (66) STAR elements were initiallyisolated from human genomic DNA and characterized in detail (Table 5).The screen was performed on gene libraries constructed by Sau3AIdigestion of human genomic DNA, either purified from placenta (Clontech6550-1) or carried in bacterial/P1 (BAC/PAC) artificial chromosomes. TheBAC/PAC clones contain genomic DNA from regions of chromosome 1 (clonesRP1154H19 and RP3328E19), from the HOX cluster of homeotic genes (clonesRP1167F23, RP1170019, and RP11387A1), or from human chromosome 22(Research Genetics 96010-22). The DNAs were size-fractionated, and the0.5-2 kb size fraction was ligated into BamHI-digested pSelect vector,by standard techniques (Sambrook et al., 1989). pSelect plasmidscontaining human genomic DNA that conferred resistance to Zeocin at lowdoxycycline concentrations were isolated and propagated in Escherichiacoli. The screens that yielded the STAR elements of Table 5 have assayedapproximately 1-2% of the human genome.

The human genomic DNA inserts in these 66 plasmids were sequenced by thedideoxy method (Sanger et al., 1977) using a Beckman CEQ2000 automatedDNA sequencer, using the manufacturer's instructions. Briefly, DNA waspurified from E. coli using QIAPREP® Spin Miniprep and Plasmid Midi Kits(QIAGEN 27106 and 12145, respectively). Cycle sequencing was carried outusing custom oligonucleotides corresponding to the pSelect vector(primers D89 and D95, Table 4), in the presence of dye terminators (CEQDye Terminator Cycle Sequencing Kit, Beckman 608000). Assembled STAR DNAsequences were located in the human genome (database builds August andDecember 2001) using BLAT (Basic Local Alignment Tool (Kent, 2002);genome.ucsc.edu/cgi-bin/hgGateway; Table 5). In aggregate, the combinedSTAR sequences comprise 85.6 kilobase pairs, with an average length of1.3 kilobase pairs.

The contents of the following references are each incorporated, in theirentirety, by this reference.

REFERENCES

-   Altschul, S. F. and Gish, W. (1996) Local alignment statistics.    Methods Enzymol, 266, 460-480.-   Altschul, S. F., Gish, W., Miller, W., Myers, E. W. and    Lipman, D. J. (1990) Basic local alignment search tool. J Mol Biol,    215, 403-410.-   Bell, A C, West, A G, and Felsenfeld, G. (2001) Insulators and    boundaries: versatile regulatory elements in the eukaryotic genome    Science 291, 447-50.-   Bennett et al. (1998) Fusion of green fluorescent protein with the    Zeocin-resistance marker allows visual screening and drug selection    of transfected eukaryotic cells. Biotechniques, 24, 478-482.-   Berger et al. (1988) Secreted placental alkaline phosphatase: a    powerful new quantitative indicator of gene expression in eukaryotic    cells Gene 66, 1-10.-   Bierhuizen et al. (1997) Green fluorescent protein variants as    markers of retroviral-mediated gene transfer in primary    hematopoietic cells and cell lines. Biochem Biophys Res Commun, 234,    371-375.-   Boivin, A, and Dura, J M. (1998) In vivo chromatin accessibility    correlates with gene silencing in Drosophila Genetics 150, 1539-49.-   Boshart et al. (1985) A very strong enhancer is located upstream of    an immediate early gene of human cytomegalovirus Cell 41, 521-30.-   Bunker, C. A. and Kingston, R. E. (1994) Transcriptional repression    by Drosophila and mammalian Polycomb group proteins in transfected    mammalian cells. Mol Cell Biol, 14, 1721-1732.-   Cherry et al. (1999) Directed evolution of a fungal peroxidase. Nat    Biotechnol, 17, 379-384.-   Chung, J H, Whiteley, M, and Felsenfeld, G. (1993) A 5′ element of    the chicken beta-globin domain serves as an insulator in human    erythroid cells and protects against position effect in Drosophila    Cell 74, 505-14.-   Deuschle, U, Meyer, W K, and Thiesen, H J. (1995)    Tetracycline-reversible silencing of eukaryotic promoters Mol Cell    Biol 15, 1907-14.-   Doll, R. F., Crandall, J. E., Dyer, C. A., Aucoin, J. M. and    Smith, F. I. (1996) Comparison of promoter strengths on gene    delivery into mammalian brain cells using AAV vectors. Gene Ther, 3,    437-447.-   Feng et al. (1999) Site-specific chromosomal integration in    mammalian cells: highly efficient CRE recombinase-mediated cassette    exchange. J Mol Biol, 292, 779-785.-   Foecking, M K, and Hofstetter, H. (1986) Powerful and versatile    enhancer-promoter unit for mammalian expression vectors Gene 45,    101-5.-   Garrick, D, Fiering, S, Martin, D I, and Whitelaw, E. (1998)    Repeat-induced gene silencing in mammals Nat Genet 18, 56-9.-   Gaszner, M., Vazquez, J. and Schedl, P. (1999) The Zw5 protein, a    component of the scs chromatin domain boundary, is able to block    enhancer-promoter interaction. Genes Dev, 13, 2098-2107.-   Gerasimova, T. I. and Corces, V. G. (1998) Polycomb and trithorax    group proteins mediate the function of a chromatin insulator. Cell,    92, 511-521.-   Gerasimova, T I, and Corces, V G. (2001) Chromatin insulators and    boundaries: effects on transcription and nuclear organization Annu    Rev Genet 35, 193-208.-   Gossen, M. and Bujard, H. (1992) Tight control of gene expression in    mammalian cells by tetracycline-responsive promoters. Proc Natl Acad    Sci USA, 89, 5547-5551.-   Graham, F. L. and van der Eb, A. J. (1973) Transformation of rat    cells by DNA of human adenovirus 5. Virology, 54, 536-539.-   Heldin et al. (1986) A human osteosarcoma cell line secretes a    growth factor structurally related to a homodimer of PDGF A-chains.    Nature, 319, 511-514.-   Henke, E. and Bomscheuer, U. T. (1999) Directed evolution of an    esterase from Pseudomonas fluorescens. Random mutagenesis by    error-prone PCR or a mutator strain and identification of mutants    showing enhanced enantioselectivity by a resorufin-based    fluorescence assay. Biol Chem, 380, 1029-1033.-   Henthorn et al. (1988) Expression of a human placental alkaline    phosphatase gene in transfected cells: use as a reporter for studies    of gene expression Proc Natl Acad Sci U S A 85, 6342-6.-   Higgins, D. G., Thompson, J. D. and Gibson, T. J. (1996) Using    CLUSTAL for multiple sequence alignments. Methods Enzymol, 266,    383-402.-   Himes, S. R. and Shannon, M. F. (2000) Assays for transcriptional    activity based on the luciferase reporter gene. Methods Mol Biol,    130, 165-174.-   Izumi, M, and Gilbert, D M. (1999) Homogeneous    tetracycline-regulatable gene expression in mammalian fibroblasts J    Cell Biochem 76, 280-9.-   Jung, R., Soondrum, K. and Neumaier, M. (2000) Quantitative PCR.    Clin Chem Lab Med, 38, 833-836.-   Kain, S R. (1997) Use of secreted alkaline phosphatase as a reporter    of gene expression in mammalian cells Methods Mol Biol 63, 49-60.-   Kao, F. T. and Puck, T. T. (1968) Genetics of somatic mammalian    cells, VII. Induction and isolation of nutritional mutants in    Chinese hamster cells. Proc Natl Acad Sci USA, 60, 1275-81.-   Kellum, R. and Schedl, P. (1992) A group of scs elements function as    domain boundaries in an enhancer-blocking assay. Mol Cell Biol, 12,    2424-2431.-   Kent, W J. (2002) BLAT—the BLAST-like alignment tool Genome Res 12,    656-64.-   Knofler et al. (2002) Human Hand1 basic helix-loop-helix (bHLH)    protein: extra-embryonic expression pattern, interaction partners    and identification of its transcriptional repressor domains Biochem    J 361, 641-51.-   Li, W-H (1997) Molecular Evolution, Sinauer Associates, Sunderland M    A., Meinke, D W, Cherry, J M, Dean, C, Rounsley, S D, and    Koornneef, M. (1998) Arabidopsis thaliana: a model plant for genome    analysis Science 282, 662, 679-82.-   Litt, M. D., Simpson, M., Recillas-Targa, F., Prioleau, M. N. and    Felsenfeld, G. (2001) Transitions in histone acetylation reveal    boundaries of three separately regulated neighboring loci. EMBO J,    20, 2224-2235.-   Morgenstern, J. P. and Land, H. (1990) Advanced mammalian gene    transfer: high titre retroviral vectors with multiple drug selection    markers and a complementary helper-free packaging cell line. Nucleic    Acids Res, 18, 3587-3596.-   Nan, X., Javier Campoy, F., and Bird A. (1997) MeCP2 is a    transcriptional repressor with abundant binding sites in genomic    chromatin. Cell 88, 471-481.-   Petersson, K, Ivars, F, and Sigvardsson, M. (2002) The pT alpha    promoter and enhancer are direct targets for transactivation by E    box-binding proteins Eur J Immunol 32, 911-20.-   Pazin, M. J. and Kadonaga, J. T. (1998) Transcriptional and    structural analysis of chromatin assembled in vitro. In Gould, H.    (ed.) Chromatin: A Practical Approach. Oxford University Press,    Oxford, pp. 172-194.-   Quong, M W, Romanow, W J, and Murre, C. (2002) E protein function in    lymphocyte development Annu Rev Immunol 20, 301-22.-   Ruezinsky, D, Beckmann, H, and Kadesch, T. (1991) Modulation of the    IgH enhancer's cell type specificity through a genetic switch Genes    Dev 5, 29-37.-   Saluz, H. P. and Jost, J. P. (1993) Approaches to characterize    protein-DNA interactions in vivo. Crit Rev Eukaryot Gene Expr, 3,    1-29.-   Sambrook, J., Fritsch, E. F. and Maniatis, T. (1989) Molecular    Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press,    Plainview N.Y.-   Sanger, F., Nicklen, S. and Coulson, A.R. (1977) DNA sequencing with    chain-terminating inhibitors. Proc Natl Acad Sci USA, 74, 5463-5467.-   Simizu, B., Rhim, J.S. and Wiebenga, N. H. (1967) Characterization    of the Tacaribe group of arboviruses. I. Propagation and plaque    assay of Tacaribe virus in a line of African green monkey kidney    cells (Vero). Proc Soc Exp Biol Med, 125, 119-123.-   Smith, R. L., Traul, D. L., Schaack, J., Clayton, G. H.,    Staley, K. J. and Wilcox, C.L. (2000) Characterization of promoter    function and cell-type-specific expression from viral vectors in the    nervous system. J Virol, 74, 11254-11261.-   Stull, R. A., Hyun, W. C. and Pallavicini, M. G. (2000) Simultaneous    flow cytometric analyses of enhanced green and yellow fluorescent    proteins and cell surface antigens in doubly transduced immature    hematopoietic cell populations. Cytometry, 40, 126-134.-   Takada, T., Iida, K., Akasaka, K., Yasue, H., Torii, R., Tsujimoto,    G., Taira, M. and Kimura, H. (2000) Evaluation of heterologous    insulator function with regard to chromosomal position effect in the    mouse blastocyst and fetus. Mol Reprod Dev, 57, 232-237.-   Tanaka, S., Livingstone-Zatchej, M. and Thoma, F. (1996) Chromatin    structure of the yeast URA3 gene at high resolution provides insight    into structure and positioning of nucleosomes in the chromosomal    context. J Mol Biol, 257, 919-934.-   Thomas, J. O. (1998) Isolation and fractionation of chromatin and    linker histones. In Gould, H. (ed.) Chromatin: A Practical Approach.    Oxford University Press, Oxford, pp. 1-34.-   Umana, P, Jean-Mairet, J, and Bailey, J E. (1999)    Tetracycline-regulated overexpression of glycosyltransferases in    Chinese hamster ovary cells Biotechnol Bioeng 65, 542-9.-   van der Vlag, J., den Blaauwen, J. L., Sewalt, R. G., van Driel, R.    and Otte, A.P. (2000) Transcriptional repression mediated by    polycomb group proteins and other chromatin-associated repressors is    selectively blocked by insulators. J Biol Chem, 275, 697-704.-   Wallrath, L. L., Swede, M. J. and Elgin, S. C. R. (1998) Mapping    chromatin structure in Drosophila. In Gould, H. (ed.) Chromatin: A    Practical Approach. Oxford University Press, Oxford, pp. 59-77.-   Weaver, L. S. and Kadan, M. J. (2000) Evaluation of adenoviral    vectors by flow cytometry. Methods, 21, 297-312.-   Wigler, M, Pellicer, A., Silverstein, S. and Axel, R. (1978).    Biochemical transfer of single-copy eukaryotic genes using total    cellular DNA as donor. Cell 14, 725-731.-   Wigley, P., Becker, C., Beltrame, J., Blake, T., Crocker, L.,    Harrison, S., Lyons, I., McKenzie, Z., Tearle, R., Crawford, R. and    et al. (1994) Site-specific transgene insertion: an approach. Reprod    Fertil Dev, 6, 585-588.-   Xu, Z. Z., Krougliak, V., Prevec, L., Graham, F. L. and Both,    G.W. (1995) Investigation of promoter function in human and animal    cells infected with human recombinant adenovirus expressing    rotavirus antigen VP7sc. J Gen Virol, 76, 1971-1980.-   Yang, T T, Sinai, P, Kitts, P A, and Kain, S R. (1997)    Quantification of gene expression with a secreted alkaline    phosphatase reporter system Biotechniques 23, 1110-4.-   Zink, D, and Paro, R. (1995) Drosophila Polycomb-group regulated    chromatin inhibits the accessibility of a trans-activator to its    target DNA Embo J 14, 5660-71.

TABLE 1 STAR elements improve transgene expression. Over- expressingFold over- Number of Plasmid clones, % expression (range) clones Empty12 3-11  25 SCS (positive control) 24 3-160 21 STAR-6 (SEQ ID NO: 6) 622-200 26 STAR-3 (SEQ ID NO: 3) 39 5-820 23 STAR-8 (SEQ ID NO: 8) 637-315 19 STAR-4 (SEQ ID NO: 4) 31 25-1500 13 STAR-1 (SEQ ID NO: 1) 575-80  23 Expression of the luciferase reporter gene is measured in celllines containing integrated pSDH plasmids, without (“empty,” thenegative control) or containing STAR elements (including the positivecontrol element, SCS from Drosophila). The mean expression level of thenegative control is defined as the reference level, and clones areconsidered over-expressing if their expression level is >2-fold abovethe reference level. The percentage of over-expressing clones for eachplasmid and the fold over-expression is reported, along with the numberof clones analyzed for each plasmid.

TABLE 2 Cloned STAR element. Chromosomal Clone location¹ Adjacent genes²Repeat sequence STAR-1 N.d. (SEQ ID NO: 1) STAR-2 N.d. (SEQ ID NO: 2)STAR-3 For 5q33.3 Chr10 part in Histone. (SEQ ID NO: 3) Rev 10q22.2Acetyltransferase gene STAR-4 For 1p31.1 No genes within 10 kb 83%repetitive (SEQ ID NO: 4) Rev 14q24.1 Intron of Regulator of G-proteinLINE2 & LTR signaling ERV_Class1 STAR-5 For 3q13.1 (SEQ ID NO: 5) Rev10q22.1* STAR-6 2p21 L5 kb Unknown putative kinase 19% SINE (MIR) (SEQID NO: 6) R 20 kb Microtuble associated 29% LINE protein STAR-7 1q32.212% Alu 4% MIR (SINE) (SEQ ID NO: 7) LINE1 2.5% L31CR1 11.5% MER1 7% Lowcomplex 2% STAR-8 9q32 ZFP KRAB box containing Zinc 35% ERV_ClassI (LTR)(SEQ ID NO: 8) Finger Protein 2% simple repeat STAR-9 See STAR4 (SEQ IDNO: 9) STAR-10 N.d. (SEQ ID NO: 10) STAR-11 2p25.1 R 15 kb unknown DNAbinding 12% Alu (SINE) (SEQ ID NO: 11) protein inhibitor (Myc type) 26%MalRs (LINE) STAR-12 5q35.3 R 15 kb unknown ADAM TS2 3% Low complexity(SEQ ID NO: 12) family metallo proteinase STAR-13 See STAR4 and 9 (SEQID NO: 13) STAR-14 F N.d. (SEQ ID NO: 14) R 20q13.33 STAR-15 1p36.36 L 6kb Voltage-gated K channel 14% LTR (MaLRs) (SEQ ID NO: 15) subunit R 4kb unknown STAR-16 F 8p23.1 No repeat on sequenced (SEQ ID NO: 16) R8p22 etc. parts STAR-17 2q31.1 L 6 kb BTEB1 transcription 10% simple andlow (SEQ ID NO: 17) factor complexity R 40 kb HNRNP ¹Chromosomallocation is determined by BLAST search of DNA sequence data from theSTAR clones against the human genome database. The location is givenaccording to standard nomenclature referring to the cytogenetic ideogramof each chromosome; e.g., 1p2.3 is the third cytogenetic sub-band of thesecond cytogenetic band of the short arm of chromosome 1(www.ncbi.nlm.nih.gov/Class/MLACourse/Genetics/chrombanding.html). F,forward sequencing reaction result; R, reverse sequencing reactionresult. N.d., not yet determined. ²Based on Human Genome Map View Build22 (www.ncbi.nlm.nih.gov/cgi-bin/Entrez/hum_srch?chr=hum_chr.inf&queryApril 2001). L, left; R, right. *Position ambiguous, several hits

TABLE 3 Sequence of various STAR elements in one strand (forward) or theopposite strand (reverse). (SEQ ID NOs:125-134). Sequence STAR3 forward(SEQ ID NO:125) STAR3 reverse (SEQ ID NO:126) STAR4 forward (SEQ IDNO:127) STAR4 reverse (SEQ ID NO:128) STAR6 forward (SEQ ID NO:129)STAR6 reverse (SEQ ID NO:130) STAR8 forward (SEQ ID NO:131) STAR8reverse (SEQ ID NO:132) STAR18 forward (SEQ ID NO:133) STAR18 reverse(SEQ ID NO:134)

TABLE 4 Oligonucleotides used for polymerase chain reactions (PCRprimers) or DNA mutagenesis (SEQ ID NOs:141-183). Number Sequence C65(SEQ ID NO:141) C66 (SEQ ID NO:142) C67 (SEQ ID NO:143) C68 (SEQ IDNO:144) C81 (SEQ ID NO:145) C82 (SEQ ID NO:146) C85 (SEQ ID NO:147) D30(SEQ ID NO:148) D41 (SEQ ID NO:149) D42 (SEQ ID NO:150) D51 (SEQ IDNO:151) D89 (SEQ ID NO:152) D90 (SEQ ID NO:153) D91 (SEQ ID NO:154) D93(SEQ ID NO:155) D94 (SEQ ID NO:156) D95 (SEQ ID NO:157) E12 (SEQ IDNO:158) E13 (SEQ ID NO:159) E14 (SEQ ID NO:160) E15 (SEQ ID NO:161) E16(SEQ ID NO:162) E17 (SEQ ID NO:163) E18 (SEQ ID NO:164) E19 (SEQ IDNO:165) E20 (SEQ ID NO:166) E21 (SEQ ID NO:167) E22 (SEQ ID NO:168) E23(SEQ ID NO:169) E25 (SEQ ID NO:170) E42 (SEQ ID NO:171) E57 (SEQ IDNO:172) E92 (SEQ ID NO:173) E93 (SEQ ID NO:174) E94 (SEQ ID NO:175) E95(SEQ ID NO:176) E96 (SEQ ID NO:177) E97 (SEQ ID NO:178) E98 (SEQ IDNO:179) D58 (SEQ ID NO:180) D80 (SEQ ID NO:181) D70 (SEQ ID NO:182) D71(SEQ ID NO:183)

TABLE 5 STAR elements of the invention, including genomic location andlength STAR Location¹ Length²  1 (SEQ ID NO: 1) 2q31.1 750  2 (SEQ IDNO: 2) 7p15.2 916  3³ (SEQ ID NO: 3) 15q11.2 and 10q22.2 2132  4 (SEQ IDNO: 4) 1p31.1 and 14q24.1 1625  5⁴ (SEQ ID NO: 5) 20q13.32 1571  6 (SEQID NO: 6) 2p21 1173  7 (SEQ ID NO: 7) 1q34 2101  8 (SEQ ID NO: 8) 9q321839  9⁴ (SEQ ID NO: 9) 10p15.3 1936 10 (SEQ ID NO: 10) Xp11.3 1167 11(SEQ ID NO: 11) 2p25.1 1377 12 (SEQ ID NO: 12) 5q35.3 1051 13⁴ (SEQ IDNO: 13) 9q34.3 1291 14⁴ (SEQ ID NO: 14) 22q11.22 732 15 (SEQ ID NO: 15)1p36.31 1881 16 (SEQ ID NO: 16) 1p21.2 1282 17 (SEQ ID NO: 17) 2q31.1793 18 (SEQ ID NO: 18) 2q31.3 497 19 (SEQ ID NO: 19) 6p22.1 1840 20 (SEQID NO: 20) 8p13.3 780 21 (SEQ ID NO: 21) 6q24.2 620 22 (SEQ ID NO: 22)2q12.2 1380 23 (SEQ ID NO: 23) 6p22.1 1246 24 (SEQ ID NO: 24) 1q21.2 94825⁵ (SEQ ID NO: 25) 1q21.3 1067 26 (SEQ ID NO: 26) 1q21.1 540 27 (SEQ IDNO: 27) 1q23.1 1520 28 (SEQ ID NO: 28) 22q11.23 961 29 (SEQ ID NO: 29)2q13.31 2253 30 (SEQ ID NO: 30) 22q12.3 1851 31 (SEQ ID NO: 31) 9q34.11and 22q11.21 1165 32 (SEQ ID NO: 32) 21q22.2 771 33 (SEQ ID NO: 33)21q22.2 1368 34 (SEQ ID NO: 34) 9q34.14 755 35 (SEQ ID NO: 35) 7q22.31211 36 (SEQ ID NO: 36) 21q22.2 1712 37 (SEQ ID NO: 37) 22q11.23 1331 38(SEQ ID NO: 38) 22q11.1 and 22q11.1 ~1000 39 (SEQ ID NO: 39) 22q12.32331 40 (SEQ ID NO: 40) 22q11.21 1071 41 (SEQ ID NO: 41) 22q11.21 114442 (SEQ ID NO: 42) 22q11.1 735 43 (SEQ ID NO: 43) 14q24.3 1231 44 (SEQID NO: 44) 22q11.1 1591 45 (SEQ ID NO: 45) 22q11.21 1991 46 (SEQ ID NO:46) 22q11.23 1871 47 (SEQ ID NO: 47) 22q11.21 1082 48 (SEQ ID NO: 48)22q11.22 1242 49 (SEQ ID NO: 49) Chr 12 random clone, and 1015 3q26.3250 (SEQ ID NO: 50) 6p21.31 2361 51 (SEQ ID NO: 51) 5q21.3 2289 52 (SEQID NO: 52) 7p15.2 1200 53 (SEQ ID NO: 53) Xp11.3 1431 54 (SEQ ID NO: 54)4q21.1 981 55 (SEQ ID NO: 55) 15q13.1 501 56 (SEQ ID NO: 56) includes3p25.3 741 57 (SEQ ID NO: 57) 4q35.2 1371 58 (SEQ ID NO: 58) 21q11.21401 59 (SEQ ID NO: 59) 17 random clone 872 60 (SEQ ID NO: 60) 4p16.1and 6q27 2068 61 (SEQ ID NO: 61) 7p14.3 and 11q25 1482 62 (SEQ ID NO:62) 14q24.3 1011 63 (SEQ ID NO: 63) 22q13.3 1421 64 (SEQ ID NO: 64)17q11.2 1414 65 (SEQ ID NO: 65) 7q21.11 = 28.4 1310 66 (SEQ ID NO: 66)20q13.33 and 6q14.1 ~2800 ¹Chromosomal location is determined by BLASTsearch of DNA sequence data from the STAR elements against the humangenome database. The location is given according to standardnomenclature referring to the cytogenetic ideogram of each chromosome;e.g., 1p2.3 is the third cytogenetic sub-band of the second cytogeneticband of the short arm of chromosome 1(www.ncbi.nlm.nih.gov/Class/MLACourse/Genetics/chrombanding.html). Incases where the forward and reverse sequencing reaction identified DNAsfrom different genomic loci, both loci are shown. ²Precise lengths aredetermined by DNA sequence analysis; approximate lengths are determinedby restriction mapping. ³Sequence and location of STAR3 has been refinedsince assembly of Tables 2 and 4. ⁴The STARs with these numbers inTables 2 and 4 have been set aside (hereafter referred to as “oldSTAR5”etc.) and their numbers assigned to the STAR elements shown in the DNAsequence appendix. In the case of oldSTAR5, oldSTAR14, and oldSTAR16,the cloned DNAs were chimeras from more than two chromosomal locations;in the case of oldSTAR9 and oldSTAR13, the cloned DNAs were identical toSTAR4. ⁵Identical to Table 3 “STAR18”.

TABLE 6 STAR elements convey stability over time on transgeneexpression¹ Cell Divisions² Luciferase Expression³ STAR6 plus puromycin42 18,000 60 23,000 84 20,000 108 16,000 STAR6 without 84 12,000puromycin⁴ 108 15,000 144 12,000 ¹Plasmid pSDH-Tet-STAR6 was transfectedinto U-2 OS cells, and clones were isolated and cultivated indoxycycline-free medium as described in Example 1. Cells weretransferred to fresh culture vessels weekly at a dilution of 1:20. ²Thenumber of cell divisions is based on the estimation that in one week theculture reaches cell confluence, which represents ~6 cell divisions.³Luciferase was assayed as described in Example 1. ⁴After 60 celldivisions the cells were transferred to two culture vessels; one wassupplied with culture medium that contained puromycin, as for the first60 cell divisions, and the second was supplied with culture mediumlacking antibiotic.

TABLE 7 Human STAR elements and their putative mouse orthologs andparalogs SEQ: ID STAR Human¹ Mouse² Similarity³ 1  1 2q31.1 2D    600 bp69% 2  2 7p15.2 6B3    909 bp 89% 3  3a 5q33.3 11B2    248 bp 83% 4  3b10q22.2 14B 1. 363 bp 89% 2. 163 bp 86% 5  6 2p21 17E4    437 bp 78% 612 5q35.3 11b1.3    796 bp 66% 7 13 9q34.3 2A3    753 bp 77% 8 18 2q31.32E1    497 bp 72% 9 36 21q22.2 16C4    166 bp 79% 10 40 22q11.1 6F1 1.270 bp 75% 2. 309 bp 70% 11 50 6p21.31 17B1 1. 451 bp 72% 2. 188 bp 80%3. 142 bp 64% 12 52 7p15.2 6B3 1. 846 bp 74% 2. 195 bp 71% 13 53 Xp11.3XA2    364 bp 64% 14 54 4q21.1 5E3 1. 174 bp 80% 2. 240 bp 73% 3. 141 bp67% 4. 144 bp 68% 15 61a 7p14.3 6B3    188 bp 68% ¹Cytogenetic locationof STAR element in the human genome. ²Cytogenetic location of STARelement ortholog in the mouse genome. ³Length of region(s) displayinghigh sequence similarity, and percentage similarity. In some cases morethan one block of high similarity occurs; in those cases, each block isdescribed separately. Similarity <60% is not considered significant.

1. A nucleotide construct comprising an expression cassette comprising apromoter operably linked to a nucleic acid sequence of interest, whereinthe nucleotide construct comprises the sequence of SEQ ID NO: 9 bothupstream and downstream of the expression cassette.
 2. The nucleotideconstruct of claim 1, wherein the nucleic acid sequence of interest is atransgene open reading frame.
 3. The nucleotide construct of claim 1,wherein the promoter is an exogenous promoter.
 4. The nucleotideconstruct of claim 1, wherein the promoter is a constitutive promoter.5. The nucleotide construct of claim 1, wherein the promoter is a viralpromoter.
 6. The nucleotide construct of claim 1, wherein the promoteris an inducible promoter.
 7. The nucleotide construct of claim 1,wherein the promoter is a CMV promoter.
 8. The nucleotide construct ofclaim 1, wherein the promoter is an SV40 promoter.
 9. The nucleotideconstruct of claim 1, wherein all copies of SEQ ID NO: 9 are directedwith their 3′ ends to the expression cassette.
 10. A DNA constructcomprising in the following order: (i) SEQ ID NO: 9; (ii) an expressioncassette comprising a promoter operably linked to a nucleic acidsequence of interest; and (iii) SEQ ID NO: 9, in opposite orientation as(i).
 11. The DNA construct of claim 10, wherein the 3′ end of SEQ ID NO:9 both in (i) and (iii) is directed to the expression cassette.
 12. TheDNA construct of claim 10, wherein the nucleic acid sequence of interestis a transgene open reading frame.
 13. An isolated cell comprising thenucleotide construct of claim
 1. 14. An isolated cell comprising thenucleotide construct of claim
 2. 15. An isolated cell comprising the DNAconstruct of claim
 10. 16. The cell of claim 13, wherein the nucleotideconstruct is integrated into the cell's genome.
 17. The cell of claim15, wherein the DNA construct is integrated into the cell's genome. 18.The cell of claim 13, wherein the cell is a Chinese Hamster Ovary (CHO)cell.
 19. The cell of claim 15, wherein the cell is a CHO cell.
 20. Thecell of claim 13, comprising multiple copies of the nucleotideconstruct.
 21. The cell of claim 15, comprising multiple copies of theDNA construct integrated into the cell's genome.
 22. A method forexpressing a nucleic acid sequence of interest in a cell, said methodcomprising: providing an isolated cell with the nucleotide construct ofclaim 1, and expressing the nucleic acid sequence of interest in thecell.
 23. A method for producing a gene product that is encoded by atransgene open reading frame, said method comprising: culturing the cellof claim 14 and expressing the transgene open reading frame in the cell.24. The method according to claim 23, wherein the gene product is aheterologous protein.
 25. The method according to claim 23, furthercomprising: isolating the gene product.
 26. A method for producing agene product in a cell, comprising: (a) providing an isolated cellcomprising a DNA construct comprising in the following order: (i) SEQ IDNO: 9; (ii) an expression cassette comprising a promoter operably linkedto a nucleic acid sequence encoding the gene product; and (iii) SEQ IDNO: 9, in opposite orientation as (i), (b) expressing the nucleic acidsequence encoding the gene product in the cell.